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List of abbreviations 
 
 
ANA  antinuclear antibody 
BCR  B cell receptor  
C3        complement component 3 
CIA  collagen-induced arthritis 
CIC  circulating immune complex 
CR1      complement receptor type1 
CR2     complement receptor type 2 
DC       dendritic cell (s) 
dsDNA           double straind DNA 
Fc R  IgG receptor 
FDC      follicular dendritic cell (s) 
FITC  fluorescein isothiocyanate 
FSC   forward scatter 
GC  germinal centre 
HEL  hen egg lysozyme 
IC         immune complex (es) 
IFN      interferon 
IL  interleukin 
ISC  Ig-secreting cells 
ITAM  Immunoreceptor Tyrosine-based Activation Motif 
ITIM  Immunoreceptor Tyrosine-based Inhibition Motif 
LHR  long homologous repeat(s) 
lpr  generalized lymphoadenopathy 
LPS  lipopolysaccharide 
MAC  membrane attack complex 
MACS             magnetic cell sorting 
MAPK  mitogen-activated protein kinase 
MFI  mean fluorescence intensity 
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NK  natural killer 
NOD  non obese diabetic 
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PBMC  peripheral blood mononuclear cell (s) 
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SHIP  Src-homology-2-domain-containing inositol 5'-phosphatase 
sIg  surface immunoglobulin 
SLE      systemic lupus erythematosus 
SLEDAI Systemic Lupus Erythematosus Disease Activity Index 
SRBC  sheep red blood cell 
SSC   side scatter 
ssDNA single-stranded DNA 
TLR  toll-like receptor 
TNF   tumor necrosis factor 
   
 













         B cells are central components of the humoral immune response, being responsible for 
the production of serum immunoglobulins. Membrane immunoglobulins displayed on their 
surface, termed the B-cell antigen receptor, allow the clonal expansion of B cells with the 
appropriate specificity during the response to infections. Several checkpoints during B-cell 
development ensure that self-reactivity is kept at a minimum, while a highly diverse (109) 
population is continuously released from the bone marrow. The secondary lymphoid organs 
provide a microenvironment suitable for the efficient presentation of antigens to B-cells. If 
additional secondary signals are present in the form of cytokines, FDC and T-cell contact, B-
cells give rise to a memory population and the antibody producing plasma cells. 
          Autoimmune pathogenesis in SLE involves complex intercellular-dependent 
pathogenetic processes with considerable heterogeneity in clinical manifestations and disease 
course. Although multiple immunologic abnormalities are important for the development and 
clinical expression of SLE, a growing body of evidence, most recently including the efficacy 
of B cell depletion therapy, supports the key role of B lymphocytes in disease pathogenesis. 
Both antibody-dependent and antibody-independent mechanisms of B cells are important in 
SLE. The pathogenic roles of B cells in autoimmune diseases occur through several 
mechanistic pathways that include autoantibodies, immune complex (IC) formation, dendritic 
cell (DC) and T cell activation, cytokine synthesis, chemokine-mediated functions, and 
ectopic neolymphogenesis. Each of these pathways participates to different degrees in 
autoimmune diseases. B lineage depletion and the inhibition of B cell activation and survival 
are beneficial in multiple autoimmune diseases and provide a basis to further explore the role 
of B cell subsets and their function in physiological and pathological conditions. 
 
1.1. The role of B cells in Systemic Lupus Erythematosus 
 
Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by autoantibodies 
directed against self-antigens, IC formation, and immune dysregulation, resulting in damage 
to essentially any organ, including the kidney, skin, blood cells, and the nervous system. The 
natural history of this illness is unpredictable; patients may present with many years of 
symptoms or with acute life-threatening disease. A large body of experimental and 
observational studies in both mice and humans indicate that B cells play complex and 
important roles in SLE. The presence of autoantibodies is the feature common to all SLE 
 6
patients. Increased production of autoantibodies leads to IC formation and tissue damage due 
to direct binding and/or deposition in tissues. Whether these antibodies are produced in 
reaction to exposure of normally nonexposed self-antigens or because of a broad spectrum of 
immune dysregulation resulting in excessive production of many antibodies without regard to 
prior stimulation, is unclear; both mechanisms may play a role. Patients with SLE make 
antibodies against DNA and other nuclear antigens, ribosomes, platelets, erythrocytes, 
leukocytes, as well as other tissue-specific antigens. The generated IC result in widespread 
tissue damage. In addition, cell-mediated autoimmune responses also play a pathophysiologic 
role (1-3). Within the healthy population, little measurable evidence exists of antibody to self. 
A subset of individuals has small amounts of autoantibody as manifested by a low-titer ANA 
or other autoantibody (4;5). Autoantibody production, by relatively few B lymphocytes, may 
be a by-product of polyclonal B-cell activation in which many more B lymphocytes are 
activated, perhaps not in response to specific antigenic stimuli (6-8). Viral stimulation of the 
immune system coupled with genetic defects in the innate and adaptive immune responses 
could lead to loss of tolerance and increase autoantibody formation (9-12). 
Autoreactive B lymphocytes are abundant in the mature peripheral B-cell repertoire 
and need to be censored to avoid autoimmunity (13). This censoring is accomplished in 
diverse ways and may be broken down by multiple mechanisms both intrinsic and extrinsic to 
the B cells. Although undoubtedly multiple immunologic abnormalities are important for the 
development and clinical expression of SLE, a growing body of evidence, more recently 
including the effectiveness of therapeutic B-cell depletion (14-19), strongly points to the B 
cell as a central player in the pathogenesis of this disease. Although self-reactive B 
lymphocytes produce the autoantibodies essential to the diagnosis of disease, B cells have 
proven in recent years to be active participants in the development of disease irrespective of 
autoantibody production (20). 
Autoantibody-independent functions that may contribute to SLE include the ability of 
B cells to regulate T cells and DCs and their ability to produce cytokines such as interleukin-
10, interleukin-6, and interferon (IFN)-  (21;22). Immunologic tolerance for self-antigens is 
enforced at several checkpoints throughout B-cell development. Although central mechanisms 
such as receptor editing and clonal deletion initiate control of autoreactivity during early bone 
marrow development, accumulating evidence supports the assumption that despite early 
tolerance checkpoints a significant fraction of autoreactive B cells proceed unchecked into the 
peripheral repertoire (23). To prevent autoimmunity additional censoring mechanisms are 
needed at later stages (23-25). Although the frequency of autoreactive B-cells significantly 
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declines in the transition from the immature B-cell stage into the peripheral mature 
compartment, as much as 20% of peripheral naive B cells are still reactive with nuclear 
antigens (26). 
 
1.2. Immune complex formation and interaction with IC-binding receptors 
 
The formation of IC due to the interaction of foreign substances with specific 
antibodies is a physiological process, which constitutes an essential part of normal immune 
defence mechanisms. Under physiological conditions IC are rapidly removed from the 
bloodstream, and provide important feedback signals for the immune system via Fc  and 
complement receptors (CR) (27-29). In some circumstances, however, potentially pathogenic 
IC might form and not be cleared properly. Large quantities of precipitating IC continue to 
circulate and become trapped and deposited in the tissues of the kidney, lung, skin, joints or 
blood vessels. These IC can fix complement and cause local damage at their sites of 
deposition (30;31). The balance between rapid and safe clearance versus tissue localization is 
fundamentally influenced by the biophysical and immunochemical properties of IC. 
It is well accepted that for the generation and control of an appropriate humoral 
immune response, in addition to signaling through the B cell receptor (BCR), a balanced 
signaling through IC-binding complement (CR1, CR2) and Fc  (Fc RI, Fc RII, Fc RIII) 
receptors is necessary. The importance of these receptors has been demonstrated in several 
autoimmune animal models (32-34). Complement containing IC may influence effector cell 
functions as well as the fate of autoreactive B cells. Alterations in the expression and/or 
function of these receptors may contribute to the initiation and/or maintenance of IC-mediated 
autoimmune disorders. Signaling pathways initiated upon the engagement of Fc - and 
complement receptors on various cell types by IC regulate autoimmune responses at different 
levels. Control of cognate interactions and inflammatory responses, IC-clearance, B cell 
selection and activation may all be affected by altered expression or function of these 
receptors. 
 
1.3. Modulation of B cell antigen-receptor signalling by cross-talk between IC-binding 
receptors 
 During the development of the humoral immune response, several mechanisms 
regulate the functions of B cells. In addition to the determining antigen-specific interaction 
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via the BCR, the fate of a B lymphocyte is strongly influenced by the integration of signals 
transduced via several other cell membrane molecules. Among those are the IC-binding cell 
membrane structures such as CR1, CR2 and Fc RII (Fig.1.). The composition, amount and 
ratio of various elements – such as Ig-isotype, complement activation fragments - in the IC 
play an important role in determining the response of B cells via their interactions with these 
receptors. The cross-talk between these cell membrane structures interacting with certain 
constituents of the complex significantly alters the quality and magnitude of the responses 

















Figure 1. Composition of IC determines possible interactions with B lymphocytes (Erdei et 
al., 2003)
 
1.4. The role of complement in autoimmune disease 
 
The complement system is comprised of a number of serum and cell membrane 
proteins that play an important role in the elimination of foreign structures and pathogens 
while protecting the host organism from complement-related damage. Complement has also 
been shown to participate in the generation of normal humoral immune responses to foreign 
antigens. Recent studies suggest that the function of the complement system may be extended 
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to include the maintenance of B cell tolerance, too. Complement activation occurs via three 
distinct pathways, known as the classical, alternative, and lectin pathways. Each of these 
routes culminates in the cleavage of major complement protein C3 by specific multi-protein 
convertase enzymes (Fig.2.) and the subsequent generation of the membrane attack complex 
(MAC). A certain portion of C3b fragments generated from C3 by cleavage becomes 
covalently attached to the activating substrate and serves as ligands, - along with C4bbound to 
antigens -, for complement receptor type 1 (CR1/CD35). Inactivation of C3b to iC3b and C3d 
generates the specific ligands for complement receptor type 2 (CR2/CD21), and serves as a 
means of targeting antigen or IC to cells expressing CR2. All these processes might link 















Figure 2. Cleavage of native C3 and generation of its biologically active fragments; 
CR1 preferentially binds C3b while the main ligand of CR2 is C3d
 
 
1.4.1. Complement receptor type 1 (CR1/CD35) 
 
 
CR1 is an approximately 200 kDa single-chain glycoprotein. The extra membranous 
portion of its most common size allotype is composed of 30 short consensus repeats (SCR). 
The 28 N-terminal SCR can be organized, based on a degree of homology, into four long 
homologous repeats (LHR) A–D, each composed of seven SCR (Fig.3.) (35). There are two 
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distinct sites on CR1 that interact with C3b and C4b. Site 1 spans SCR 1–3 in LHR A, and 
binds C4b and, weakly, C3b. Site 1 also carries decay-accelerating activity for the C3 
convertases. Site 2 spans SCR 8–10 in LHR B and the nearly identical SCR 15–17 of LHR C, 
and binds both C3b and C4b efficiently, although it has a higher affinity for C3b. It is also the 
major site of CR1 cofactor activity and is indispensable for the decay-accelerating activity of 









Figure 3.The structure of human complement receptor type 1, showing 30 SCR organized in 
four LHR and their functions (Atkinson et al., 2002)
 
 
CR1 is expressed by all peripheral blood cells except platelets, natural killer cells and 
most T lymphocytes (39). In tissues, it is expressed by follicular dendritic cells (FDC), 
glomerular podocytes and some astrocytes. In the circulation, CR1 on erythrocytes is an 
immune adherence receptor that binds C3b/C4b-opsonized immune complexes and ferries 
them to the liver and spleen for removal (40). Another function of CR1, facilitated by its 
ability to bind C3b and C4b, is the retention of opsonized antigens necessary to maintain 
immunological memory on FDC in germinal centers (GC) (41;42). In addition to its ligand-
binding capability, CR1 has decay-accelerating activity for C3- and C5-convertases. By 
limiting the deposition of C3b and C4b, this decay-accelerating activity might regulate the 
size of immune complexes, and prevent excessive complement activation. CR1 also possesses 
cofactor activity for the limited cleavage of C3b and C4b by the plasma serine protease, factor 
I (43). Cleavage of C3b by factor I, with CR1 as cofactor, generates C3dg. This fragment and 
C3d, the final cleavage product of C3, interact with complement receptor type 2 on B cells, 
thus lowering the threshold for B-cell activation by the antigen receptor (44-46). Recently, 
CR1 was also shown to bind C1q and mannan-binding lectin, raising the possibility that they 
too, along with C3b and C4b, contribute to CR1-mediated immune adherence (47;48). 
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Whereas the role of human CR2 in B cell activation is relatively well-established, much less is 
known about the exact function of CR1 (CD35). Data presented by our group indicate that 
CR1 expressed by human B lymphocytes mediates inhibitory signals, thus plays an opposite 
role to CR2 in the regulation of B cell activation (49). C3b-like C3, which mimics multimeric 
C3b and binds to CR1, strongly and dose-dependently inhibits the anti-IgM-induced 
proliferation of human B cells. Parallel to this, the anti-IgM-induced transient increase of 
intracellular free Ca2+ level and phosphorylation of tyrosine residues of several cytoplasmic 
proteins are also inhibited by multimeric C3 (49).  
 
 
1.4.2. Complement receptor type 2 (CD21) 
 
 
CR2 is a surface glycoprotein located almost exclusively on B cells and FDC in mice, 
with a somewhat broader tissue distribution in humans. In mice, both CR1 and CR2 are 
transcribed from a single gene by alternative mRNA splicing, while in humans these proteins 
are derived from two distinct but closely linked genes on chromosome 1 (50). Both human 
and mouse CR2 bind the C3 activation products iC3b, C3dg, and C3d; human CR2 also binds 
Epstein–Barr virus, CD23, and interferon-  CR2 is composed of 15 repeating 60–70 
amino acid extracellular subunits termed short consensus repeats (SCR), a transmembrane 
domain, and a short cytoplasmic tail. In humans, a 16SCR form of CR2 has been identified 
that is generated by alternative splicing of a single exon (53).  
Expression of CR2 on B cells is regulated in a cell-type specific manner and depends 
on the developmental stage. CR2 is first expressed at the T1-T2 transitional stage on 
B220low/IgMhigh B cells and is terminated when they finish their maturation and differentiate 
into plasma cells (54). While terminally differentiated plasma cells lack CR2, memory B 
lymphocytes express this complement receptor. FDC, which capture antigen complexes in 
GC,constitutively express CD21. In the splenic compartment the highest levels of receptor 
expression are found on marginal zone B lymphocytes followed by follicular B cells 
expressing intermediate CR2 level (55). Non-conventional B1 cells have the lowest CR2 
density on their surface. 
In humans, during B cell development in the bone marrow, CR2 is primarily expressed 
on IgM+/IgD- cells, although expression on a small subpopulation of CD19+/IgM- pre-B cells 
has also been described. CR2 is expressed almost on all mature peripheral human B 
lymphocytes. Similar to mice, expression of human CR2 on splenic B cells is highest in the 
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marginal zone subpopulation and lost from plasma cells along with other surface molecules 
characteristic for B cells (56). 
CR2 has been demonstrated to amplify antigen-induced B cell activation through 
surface IgM (sIgM), to rescue peripheral B cells from sIgM-mediated apoptosis, to promote 
antigen processing and presentation of C3d-bound targets, to modulate the expression of 
costimulatory molecules, to stabilize the B cell receptor in lipid rafts, and to target IC to GC 
in secondary lymphoid organs (57-61). Many of these functions may occur via interaction of 
CR2 with CD19 and CD81 on the B cell surface, where these receptors form a multi-
molecular signal transduction complex. Mice made deficient in CR2 by homologous 
recombination have defects in T-dependent and T-independent antibody responses, GC 
formation, generation of memory B cells, and the development of a normal natural antibody 
repertoire. The defect in T-dependent antibody responses results from a lack of CR2 on both 
B cells and FDC.  
 
1.4.3. Possible relationship between CR1/CR2 and the development of autoimmunity in 
mice 
 
In the B6/lpr mouse model of lupus, CR1/CR2 deficiency results in the earlier onset of 
a more aggressive disease. On a mixed B6/129 background, CR1/CR2-deficient lpr mice 
develop marked splenomegaly and lymphadenopathy, increased anti-nuclear and anti-dsDNA 
antibodies, and increased glomerular deposits of IC (62). In mice expressing transgenes for 
hen egg lysozyme (HEL) and HEL-specific membrane Ig, the lack of CR1/CR2 resulted in 
impaired induction of tolerance. In the absence of CR1/CR2, HEL-specific B cells were not 
anergized and were found to be accumulated in secondary lymphoid organs with an increased 
life-span. Since both CR1 and CR2 are deficient in these animals, a specific effect of CR2 
deficiency cannot be assessed (63). This double-transgenic model supports a role for 
CR1/CR2 in negative selection, suggesting that complement may be involved in the 
maintenance of tolerance. In one report, the effect of C4 deficiency in these models mimicked 
those of CR1/CR2 deficiency, suggesting that the primary effect on B cell tolerance was 
mediated by CR1 in its interactions with C4 activation fragments. The Cr2 gene is 
demonstrated to be a strong candidate for lupus susceptibility in NZM2410 mice, which is 
widely used as a model of lupus (64). Biochemical analyses of CR1 and CR2 in these mice 
revealed that both proteins are increased in molecular weight because of a single nucleotide 
polymorphism in the ligand-binding domain. Molecular modelling of the mouse CR2 
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sequence revealed that the altered amino acid (asparagine) is located at a site in the human 
receptor that is critical for receptor dimerization. Glycosylation of this asparagine residue 
would alter receptor dimerization. Subsequent functional analyses demonstrated defects in 
C3d-ligand binding as well as signaling mediated by CR2. Because the functions of CR2 were 
affected in this model, these data support a role for CR2 in the development of the 
autoimmune phenotypes observed. 
The exact mechanisms by which CR2 plays a role in B cell tolerance have also not yet 
been delineated. Since coligation of CR2 with sIg is known to lower the threshold for B cell 
activation, one hypothesis is that coligation of CR2 with sIg also lowers the threshold for B 
cell tolerance to autoantigens. If CR2 expression or function is impaired, then autoreactive B 
cells may be able to escape from tolerance. Altered CR2 expression or function may also 
diminish the levels of complement-coated autoantigens that are targeted to FDC in secondary 
lymphoid organs, and remove a reservoir of self-antigens that may be critical in maintenance 
of self-tolerance. Expression of CR2 on both B cells and FDC is important in the generation 
of normal immune responses, and ligand binding to both cell types may also be important in 
the regulation of B cell tolerance. 
CR2 may indirectly regulate B cell tolerance via effects on T cell tolerance, too. CR2 
has been shown to bind and internalize antigen for presentation to T cells (65). Since CR2-
mediated antigen presentation in the absence of sIg coligation does not result in upregulation 
of costimulatory molecules, this mechanism may be important in the regulation of T cell 
tolerance (66). In addition, coligation of CR2 with sIg may alter the levels or types of 
costimulatory molecules upregulated, and thus skew the T cell cytokine profile to create an 
environment that favors loss of tolerance to self-antigen. In the cardiac myosin-induced model 
of experimental autoimmune myocarditis, which is believed to be mediated by autoreactive T 
cells, complement depletion, CR1/CR2 blockade or deficiency markedly decreased the 
incidence and severity of myocarditis. In addition, reduced levels of proinflammatory 
cytokines (TNF- , IL-1 and IFN- ) and increased levels of an anti-inflammatory cytokine 
(IL-10) were noted in these animals, as well as decreased autoantibody titers of total IgG. 
These data suggest that CR1/CR2 regulates the production of proinflammatory cytokines by 
autoreactive T cells, with an associated increase in autoantibody production resulting in the 
induction of autoimmune myocarditis. Although these results contrast with those observed in 
the B6/lpr and HEL double transgenic models, it is possible that in certain autoimmune 





1.4.4. Alterations of CR1/CR2 receptor expression in human autoimmune diseases 
 
Contribution of complement receptors CR1 (CD35) and CR2 (CD21) to the initiation 
and sustenance of tissue damage was studied in various animal models. The findings support 
the notion that malfunctioning of CR1/CR2 might be involved in the breakdown of tolerance 
and excessive autoantibody production by autoreactive B cell clones. Results obtained from 
mouse experiments however should be extended to human system with great care, since there 
are basic differences between the structure and function of human and murine CR1 and CR2. 
As mentioned earlier in the mouse CR1 and CR2 are coded by one gene and the receptors are 
generated by alternative splicing. In contrast to this, different genes encode human CR1 and 
CR2. While murine CR2 shows structural and functional homology to human CR2 and has a 
similar expression pattern, human CR1 is functionally distinct from murine CR1; moreover its 
tissue distribution greatly differs in these two species.  
While CR1 expressed on mouse B cells have a similar role as CR2, in humans they 
have distinct functions. Regarding their role in B cell activation probably the most important 
function of CR2 is its capacity to promote B cell activation by lowering the signaling 
threshold of antigen-specific BCR (46). In contrast, human CR1 clustered on anti-  
activated human B lymphocytes have been shown to induce negative regulatory signals (49), 
a phenomenon also demonstrated recently on human T cells (67). Thus, in humans, depending 
on the actual composition of IC and the degradation stage of C3 and C4 in the complex, CR1 
and CR2 may influence the fate of autoreactive B cells differently.  
Expression of CR2 and CRl on human B cells has been studied in a number of human 
autoimmune diseases. One important observation is that patients with SLE demonstrate 
abnormalities in the expression of both CR2 and CRl on B lymphocytes (68;69). Peripheral B 
cells show a marked decrease in both CR2 and CRl density as compared to control subjects. It 
has also been reported that CR2 expression is strongly reduced on synovial B cells of arthritis 
patients as compared to their peripheral B cells (70).  
The functional consequences of reduced complement receptor expression in human 
diseases have been quite rarely studied so far. In one of these investigations B cells from SLE 
patients were stimulated with an anti-IgD antibody conjugated to the Epstein-Barr virus 
gp350 protein, which binds to CR2. Despite the fact that these B cells were found to express 
half as many surface CR2 as normal B cells, the Ca2+ response and the percentage of 
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responding cells were significantly increased (71). These observations suggest that CR2 may 
be involved in the exaggerated autoreactive B cell activity as a regulator, independent of its 
density on the cell surface. 
 
1.5. The role of Fc R on B cells  
 
Fc Rs are widely expressed throughout the immune system (72). By binding the 
antibody Fc-portion, they provide a link between the specificity of the adaptive immune 
system and the powerful effector functions triggered by innate immune effector cells. In all 
mammalian species studied to date, four different classes of Fc  receptors have been defined: 
Fc RI (CD64), Fc RII (CD32), Fc RIII (CD16), and Fc RIV (72). Whereas Fc RI displays 
high affinity for the antibody-constant region and restricted isotype specificity, Fc RII and 
Fc RIII have low affinity for the Fc region of IgG but a broader isotype-binding pattern. 
Fc RIV, a recently identified receptor conserved in all mammalian species reacts with Ig with 
intermediate affinity and restricted subclass specificity. Functionally, there are two different 
types of Fc R: the activating and the inhibitory receptors, which transmit their signals via 
immunoreceptor tyrosine-based activation (ITAM) or inhibitory motifs (ITIM), respectively. 
The paired expression of activating and inhibitory molecules on the same cell is the key for 
the generation of a balanced immune response. Additionally, it has only recently been 
appreciated that the IgG Fc receptors show significant differences in their affinity for 
individual antibody isotypes, rendering certain isotypes more strictly regulated than others.  
Murine models of autoimmune diseases indicate the roles of the inhibitory Fc  
receptor in the suppression of such disorders, whereas activating-type Fc R are crucial for the 
onset and exacerbation of the disease (73-76). Activating and inhibitory Fc R that are co-
expressed on the same cell set a threshold for immune cell activation by IC. Besides their 
involvement in the efferent phase of an immune response, they are also important for 
modulating adaptive responses by regulating B cell activation. Uptake of IC by Fc R on DC 
and the concomitant triggering of activating and inhibitory signaling pathways will determine 
the strength of the initiated T-cell response. Loss of this balanced signaling results in 
uncontrolled responses that can lead to the damage of healthy tissues and ultimately to the 
initiation of autoimmune processes. There are several factors that can influence the balance 
between activation and inhibition, such as the expression levels of activating versus inhibitory 
receptors and the modulation of their ratio by cytokines (77-79). The pathogenicity of an 
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autoimmune response will be determined by both cytokine-mediated regulation of class 
switching and the changes of expression levels of the responsible activating versus inhibitory 
Fc  receptors. 
 
1.5.1. The inhibitory Fc RIIB 
 
           Fc RIIB belongs to the family of immune inhibitory receptors. These proteins can be 
found on a wide variety of immune effector cells, share similar properties, and are important 
regulators of their activating counterparts (80). The loss of these negative regulators leads to 
imbalanced immune responses resulting in autoimmunity and overt autoimmune disease 
(81;82). Fc RIIB is a single-chain receptor that carries an ITIM motif in its cytoplasmic 
domain, a hallmark of this inhibitory protein family. It functions through the recruitment of 
the inositol phosphatase SHIP through binding to an SH2 site generated on the Fc RIIB ITIM 
motif as a consequence of the transphosphorylation that is initiated upon its coligation to an 
ITAM-bearing receptor. It is the only “classical” Fc  receptor on B cells where it regulates 
activating signals delivered to the BCR by IC retained on the FDC (83). 
 
1.5.2. Fc RIIB as a regulator of B cell activation 
 
Because of its role in regulating BCR signals, which ultimately will decide whether a 
B cell proliferates, undergoes class switching, and matures into an antibody-secreting plasma 
cell, Fc RIIB has been suggested to play an important role in maintaining peripheral 
tolerance. When coligated with the BCR, it triggers two ITIM-dependent signaling pathways 
that inhibit cell activation and proliferation. While regulation of cell activation is dependent 
on the recruitment of SHIP to the ITIM motif which ultimately leads to the inhibition of 
calcium-dependent signaling pathways, control of proliferation seems to involve SHIP-
independent signaling pathways, including the adaptor molecule Dok and MAP kinases (84). 
Besides these ITIM-dependent signaling events, the crosslinking of Fc RIIB on B cells 
independent of BCR is known to lead to B cell apoptosis (85;86). The capacity of Fc RIIB to 
trigger B cell apoptosis has been proposed to be another mechanism for controlling B cell 
responses and maintaining self tolerance by deletion of low-affinity or self-reactive B cells 
(86). This hypothesis was supported by the generation of Fc RIIB-deficient mice that 
spontaneously develop a lupus-like disease characterized by the production of autoantibodies. 
This autoimmune phenotype is strain dependent, indicating that other epistatic modifiers are 
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involved in disease susceptibility and severity. Autoimmune-prone mouse strains such as 
NZB, NOD, BXSB, and MRL express reduced levels of Fc RII receptor on activated and 
germinal-center B cells, which has been attributed to a polymorphism in the promoter of this 
gene (87-90). More recently, a similar polymorphism in the human Fc RIIB promoter that is 
linked to lupus has been identified (91). Additionally, a polymorphism in the transmembrane 
domain of Fc RIIB has been identified, which was associated to human SLE. This allelic 
variant of the inhibitory receptor loses its function due to the inability to associate with lipid 
rafts (92;93). It has been described that transfer of Fc RIIB-deficient bone marrow into 
irradiated RAG or IgH knockout recipients leads to the development of autoimmunity. In 
these animals, the monocytic compartment still expressed Fc RIIB while it was absent from 
peripheral B cells (94). Moreover, induced up-regulation of Fc RIIB expression on B cells to 
wild-type levels by retroviral transduction restore tolerance and thus prevent the development 
of the fatal autoimmune disease. Restoration of Fc RIIB expression to wild-type levels on 
approximately 40% of peripheral B cells was sufficient to prevent the development of 
autoantibodies and autoimmune glomerulonephritis (95). To protect against autoimmunity it 
was not necessary to restore Fc RIIB function on all B cells. This finding has important 
implications for the design of therapeutic approaches, as it suggests that despite the complex 
nature of autoimmune diseases, therapeutic effects are achievable by targeting specific cell 
populations. 
In another experiment overexpression of Fc RIIb on B cells reduced IgG production 
and the development of spontaneous SLE in mice (96). These results clearly demonstrate the 
contrasting roles played by Fc RIIb on B cells and macrophages in the control of 
autoimmunity, and emphasize the therapeutic potential for modulation of Fc RIIb expression 
on B cells in autoimmune disease. 
The stages in B cell development at which Fc RIIB exerts its function in the 
maintenance of tolerance has recently been defined. Autoreactive B cells can be generated at 
several stages during B cell ontogeny. There is accumulating evidence that Fc RIIB mediates 
its function during late stages of B cell maturation, thus representing a distal checkpoint. 
Fc RIIB deficiency did not influence early events in the bone marrow like receptor editing, 
nor did it prevent the development of IgM-positive autoreactive B cells. After class switching 
to IgG, however, Fc RIIB was essential to prevent the expansion of autoreactive B cells and 
their maturation into plasma cells (97). As IgG has higher pathogenic potential than IgM, a 
relatively late stage of Fc RIIB-mediated negative regulation might be sufficient to prevent 
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the initiation of severe autoreactive processes. Altered regulation of Fc RIIb expression, 
caused by either genetic or disease activity related factors, could contribute significantly to the 




Figure 4. Fc R can initiate or augment an immune response at the initial antigen-
presentation step (a) by facilitating immune complex (IC) uptake, and can drive cellular (b)
and humoral (c) immune responses. (Takai et al., 2002)
 
 
1.6. SLE and memory B cells 
 
1.6.1. The role of IC-binding receptors on memory B cells 
 
Humoral memory for foreign antigens is essential for long-term protection against 
invading pathogens. However, autoreactive memory cells may have life-threatening 
consequences in autoimmune diseases such as SLE, a disease associated with a breakdown in 
B cell tolerance and elevated serum levels of high-affinity IgG autoantibodies. In addition to 
altered tolerance of IgG-producing B cells, individuals with SLE show abnormalities in early 
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B cell tolerance checkpoints, leading to increased numbers of autoreactive mature naïve B 
cells independent of disease activity (98). Naïve B cells do not secrete antibodies, but antigen-
mediated activation induces their differentiation into antibody-secreting short-lived 
plasmablasts and long-lived plasma cells or memory B cells. The finding that high 
frequencies of autoreactive naïve B cells are present in SLE patients suggests that these cells 
might be the precursors of high-affinity IgG+ B cells contributing to humoral autoimmunity in 
SLE. Alternatively, defects that lead to abnormalities in memory B cell tolerance in SLE 
might be independent of the earlier tolerance defects.  
The relative contribution of IgG+ memory B cells to the production of serum 
autoantibodies in SLE is not known, but memory B cells readily respond to activation by 
differentiation into antibody-secreting B cells. Indirect evidence for a role of memory B cells 
in human autoimmune diseases comes from clinical studies with rituximab, a monoclonal 
anti-CD20 antibody that efficiently depletes all circulating B cells. Recent evidence suggests 
that relapses after anti-CD20 therapy are strongly associated with the reappearance of high 
numbers of circulating memory B cells (99). However, it is not yet clear whether this reflects 




1.6.2. Development of antigen-specific memory B cells 
 
Memory B lymphocytes are mainly generated in the GC of secondary lymphoid 
organs. Within these structures proliferating B cell blasts can increase the affinity of their 
surface Ig through somatic hypermutation of their Ig variable region genes and positive 
selection of high affinity mutants. Isotype switch can also take place during GC reaction. 
After leaving the GC, memory B cells either join the recirculating pool of lymphocytes, or 
home to antigen draining sites such as the marginal zone of the spleen. Memory B cells 
display several intrinsic differences compared with naive B cells, i.e.: (a) lower threshold for 
activation, (b) ability to directly present antigen to helper T cells, and (c) longer life span.  
Helper T (Th) cell–regulated B cell immunity progresses in an ordered cascade of 
cellular development that culminates in the production of antigen-specific memory B cells. 
The recognition of peptide MHC class II complexes on activated antigen-presenting cells is 
critical for effective Th cell selection, clonal expansion, and effector Th cell function 
development. Cognate effector Th cell–B cell interactions then promote either development of 
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short-lived plasma cells (PC) or GC. These GC expand, diversify, and select high-affinity 
variants of antigen-specific B cells for entry into the long-lived memory B cell compartment. 
Upon antigen re-challenge, memory B cells rapidly expand and differentiate into PC under the 
















Figure 5. B cells can either differentiate into long-lived plasma cells, or remain as non-
secreting precursors for antigen recall. (Louise et al., 2005) 
 
1.6.3. Maintenance of serological memory by polyclonal stimuli 
 
Whether persisting antigen is required to maintain serological memory remains 
debated. Antigen-driven proliferation and differentiation of memory B cell to short-lived 
plasma cells induce high levels of protective antibodies. Yet, if persistence of antigen were the 
only mechanism available to maintain antibody production, immunological memory would be 
limited to persisting antigens. All these suggest that there should be a so far unrevealed 
alternative mechanism that may ensure sustained proliferation and differentiation of memory 
B cells, independently of persisting antigen (101). 
Under in vivo conditions there are two types of polyclonal stimuli that can trigger B 
lymphocyte proliferation and differentiation in the absence of antigen. Microbial structures 
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such as LPS or unmethylated DNA motifs (CpG oligonucleotides), which stimulate B cells via 
TLR4 and TLR9, respectively or stimuli by activated bystander T cells, which stimulate B 




















Figure 5. TLR expression and function on human B cell subpopulations 
 
Detailed studies on human B-cell populations have shown that blood–derived naive and
memory B cells express distinct levels of TLR6, 7, and 9. Indeed, TLR6, 7, 9, and 10 are
barely expressed by circulating naive B cells whereas memory B cells display a higher




 In the antigen-dependent response mode, memory B cells undergo a massive 
expansion and differentiation to become short-lived plasma cells. This response is transient, 
because of the negative feedback exerted by the high level of antibody present. However, 
some plasma cells generated in this way become long-lived if rescued in available niches such 
as the bone marrow. These cells sustain serum antibody levels, but can do so only for a few 
months, because of their limited life span. In contrast, in the polyclonal response mode, all 
memory B cells respond to environmental stimuli by undergoing continuous proliferation and 
differentiation. In this way, a constant level of plasma cells and serum antibodies could be 
maintained throughout a human life span. Because this mechanism is non-specific, it would 
act indiscriminately to maintain the broad spectrum of antibody specificities generated during 
the antigen-driven immune response (101). 
 22
B cells were the first human immune cell subset known to recognize CpG motifs 
within microbial DNA. Based on B-cell activation and proliferation, the human CpG motif 
was identified and an oligo-nucleotide was developed (CpG ODN 2006) that triggered the 
MAP kinase pathway and NF B translocation in purified B cells. This sequence turned out to 
be a potent adjuvant to support humoral immune responses in primates (105-107). Foreign 
CpG-DNA from viruses and bacteria can activate memory B cells through binding to TLR9, 
and this pathway has been hypothesized to be involved in the continuous activation of 
memory B cells ensuring life-long humoral immunity (101). 
The discrimination between human and bacterial/viral DNA is based on the fact that 
CpG dinucleotides are underrepresented and generally methylated in vertebrate DNA, while 
they are present at expected frequency and are unmethylated in bacteria and viruses. Bacterial 
infection has been suspected as a triggering factor for lupus and TLR9 has been implicated in 
the activation of autoreactive B cells in vitro. Its role in promoting autoantibody production 
and disease in vivo, however, has not been determined (108-110).   
1.6.4. IgM memory B cells 
 
 
In mice, memory B cells have mostly switched from the initial expression of IgM to 
that of other Ig classes and the frequency of memory B cells is about 5% of all peripheral B 
lymphocytes. In the human this ratio is much higher;i.e. 25%. The difference might largely be 
explained by the longer life span of humans, leading to the accumulation of a much larger 
fraction of memory B cells. 
In humans, B lymphocytes expressing cell surface IgM and CD27 comprise a 
significant proportion of the B-cell population in the peripheral circulation. These cells have 
been termed IgM memory B cells because, like conventional class-switched memory cells, 
they possess somatically hypermutated variable region genes and express CD27 (111). 
The splenic marginal zone (MZ) has been implicated as a source of circulating IgM 
memory B cells, as their representation in the peripheral circulation is reduced in asplenic 
subjects, and their progressive appearance in the peripheral circulation during the first and 
second year of life correlates with the development of the splenic MZ (112). Although it 
presently cannot be ruled out that IgM+/CD27+ B lymphocytes are generated in a GC-
independent pathway, these observations collectively suggest that these cells, besides class-
switched memory cells, represent a second, phenotypically defined memory B cell subset 
present in human blood.. 
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In vitro-activated IgM memory B cells differentiate into plasma cells, but do not 
change isotype even under conditions that promote switching. This indicates that IgM 
memory B cells are committed to secrete IgM. The role of IgM- expressing memory cells in T 
cell-dependent immune responses remains elusive. Pentameric IgM enables efficient cross-
linking of antigen and permits a strong activation of the complement system. These features 
are advantageous in the defence against bacteria. Since IgM memory B cells require the 
spleen for their generation and/or survival and are responsible for the protection against 
encapsulated bacteria, splenectomized and asplenic patients have a high incidence of 






Studies in animal models have suggested that genetically determined abnormalities in IC-
binding Fc  and complement receptors may have a causative role in autoimmune 
disordersThe pathogenic potential of these receptors in human autoimmune disorders is still 
controversial. Since B cells play complex and important roles in SLE, alterations in the 
expression of IC-binding receptors expressed on the surface of their various subsets may 
contribute to the dysregulation of several B cell functions. An appropriate cross-talk between 
these receptors is necessary to control immune responses by B cells. 
 
 
Our aims were 
 
1. To describe the expression pattern of Fc RII (CD32), complement receptors type 
1(CD35) and 2 (CD21) as well as membrane Ig on naïve, IgM+ and IgG+ memory B 
cells of healthy individuals.  
 
2. To compare the expression pattern of these IC-binding receptors on distinct B cell 
subpopulations in SLE patients and healthy individuals. 
 
3. To reveal the effect of CR1 clustering on CpG and- BCR –induced proliferation of 
naïve, IgM+ and IgG+ memory B cells from healthy donors. 
 
4. To describe how ligand-induced clustering of CR1 modulates CpG and BCR-induced 
antibody-producing plasmablast differentiation of IgM+ and IgG+ memory B cells. 
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RPMI medium 1640+10%FCS 
 
RPMI powder Dissolved in 1000ml distilled water 
NaHCO3 2 mg/ml 
Na-piruvate 0.22 mg/ml 
L-glutamine 2mM 
Streptomcyin 0.1 mg/ml 





NaCl 8 g/l 
KCl 0.4 g/l 
NaH2PO4 1.77 g/l 
Na2HPO4 0.77 g/l 
D-glucose 2 g/l 








TMB buffer (pH5.5) for ELISA 
 
Na-acetate 0,1 M 
 
PBS buffer (pH 7.4)  
 
NaCl 8 g/l 
KCl 0,2 g/l 
Na2HPO4*H2O 1,4 g/l 















Sample buffer (2X) for SDS-PAGE 
 
Tris/HCI (pH 6.8) 125 mM 
SDS (10%) 2% 
Glycerol 20% 
BromphenolBlue (4%) 0,001% 
2-ME 2% 
 
Running buffer for SDS-PAGE (pH 8.3) 
 
Tris 3g/l 
SDS (10%) 10ml/l 
Glycin 14.4 g/l 








Distilled water Up to 1000ml 
 
 





N,N-dimethyl  formamide Up to 10ml 
 
  
AEC buffer for ELISPOT (pH 5.0) 
 
Acetic acid (0,2M) 148ml 
Sodium acetate (0,2M) 352ml 







 Name                                Host                     Origin
a-hCD27-PE                         mouse                                Caltag
a-hCD32-FITC                     mouse                                  BD Pharmingen
a-hCD35-PE                         mouse                                BD Pharmingen
a-hCD35-FITC                     mouse                                  Southern Biotech
a-hCD21-FITC                     mouse                                  Dako
a-hIgG-AlexaCy5                  goat                                Jackson ImmunoResearch 
a-hIgM-AlexaCy5                 goat                                Jackson ImmunoResearch 
a-hCD19-biotin                    mouse                                 BD Pharmingen
a-hIgG-HRPO                       rabbit                               Dako
a-hIgM-HRPO                      rabbit                                Dako
a-hIgG F(ab’)2                                 goat                               Jackson ImmunoResearch  
a-hIgM F(ab’)2                                goat                               Jackson ImmunoResearch













3.2.1. Patients and controls 
 
Twenty-three patients with SLE (20 females, age 39 ± 5 years; 3 males age 44 ± 10 
years) were involved in the present study. As controls, 30 age- and sex-matched subjects with 
no clinical or laboratory signs of an inflammatory rheumatic disease were included. All 
patients satisfied the criteria for a definitive diagnosis of SLE (115). Of the 23 SLE patients, 
15 were  receiving corticosteroids (equivalent to 5–25 prednisone mg/day) and 8 were treated 
with immunosuppressive drugs, including hydroxychloroquine (n=2, 200 mg/day) and 
azathioprine (n=5, 50 mg/day) or methotrexate (n=3, 12.5-20 mg/wk). Disease activity was 
assessed by the SLE disease activity index (SLEDAI) score (115;116). 15 patients had a 
SLEDAI 10 and were considered relatively inactive. The remaining 8 patients with SLEDAI 
>10 were considered active. The study was approved by the local ethical committee 
(Institutional Review Board of National Institute of Rheumatology and Physiotherapy) and 
written informed consent was obtained from each participant. 
 
3.2.2. Flow cytometry 
 
Immunofluorescence measurements were performed using a FACSCalibur flow 
cytometer and the CellQuest software (BD Biosciences, Mountain View, CA). Peripheral 
blood mononuclear cells (PBMCs) from individual patients and controls were isolated from 
heparinized blood by Ficoll Hypaque (Amersham Biosience) density gradient centrifugation 
and washed twice in PBS. On the basis of forward (FSC) and side scattering (SSC) properties 
lymphocytes were differentially counted. A total of 3*105 PBMC were washed in PBS, and 
were stained using the appropriate antibodies according to the manufacture’s instruction. 
CD19+ B cells were generally stained with FITC, PE and AlexaCy5 conjugated monoclonal 
antibodies to CR1, CR2, sIgG/IgM, Fc RII and CD27. After incubation on ice for 30 min., 
cells were washed and were resuspended in 200 l PBS containing 1% FCS and 0.15 NaN3. 
Data of 100,000 cells were collected. Relative fluorescence intensity (RFI) was obtained by 
dividing the mean fluorescence intensity (MFI) of the sample with isotype-matched control.  
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3.2.3. B-cell preparation 
 
3.2.3.1. B cell preparation from blood 
 
Heparinized blood was mixed with an equal volume of PBS at room temperature and 
slowly layered over the Ficoll-Hypaque solution. After centrifugation at 2000 rpm for 30 min 
at 18 C with no brake, mononuclear cells were isolated and washed three times with PBS. 
Cells were finally resuspended in complete RPMI 1640 medium. Monocytes were depleted by 
plastic adherence, while T cells were depleted by rosette formation using 2-
aminoethylisothiouronium bromide (AET) treated sheep red blood cells (SRBC) followed by 
separation of rosette-forming cells on Ficoll-Hypaque gradient. The purity of the CD19+ B 
cells was usually over 80% (< 2% CD14+, < 8% CD3+and < 10% CD56+) as measured by 
flow cytometry. 
 
B cells were alternatively isolated from PBMCs by negative selection using magnetic 
separation (Miltenyi Biotec Inc.). Fc-receptor-blocking Ab and non-B-cell hapten antibody 
coctail was added to freshly isolated mononuclear cells followed by an anti-hapten Ab 
coupled to magnetic microbeads. Cells were then passed through a magnetic column and B 
cells were collected in the flowthrough fraction. Over 95% of the cells obtained were CD19+ 
with no detectable CD3+ and CD14+ cells in the suspension. 
 
3.2.3.3. Isolation of CD27+ memory B cells 
 
CD27+ memory B cells and CD27- naïve cells were separated by magnetic cell sorting. 
Isolated B cells were passed through 30 m nylon mesh to remove cell clumps. 5x107 cells 
were mixed with CD27 microbeads and incubated for 30 minutes at 4 C. Cells were washed 
three times by adding 1-2 ml PBS containing 0,5% BSA. The cell suspension was loaded onto 
a column, which was placed in the magnetic field of a MACS Separator. The magnetically 
labeled CD27+ memory B cells were retained on the column, while the unlabelled naïve B 
cells run through. After removal of the column from the magnetic field, the retained memory 






3.2.4.1. RNA extraction 
 
Total RNA was extracted from magnetic separated B cells using TRI reagent (Sigma) 
according to manufacturer’s instructions (Chomczynski and Sacchi, 1987). 400 l of TRI 
reagent (Sigma) was added to 5x106 cells. The cell extract was pipetted up and down 20 times 
until homogeneity. Samples were allowed to stand for 7 minutes at room temperature for 
complete dissociation of nucleoprotein complexes. 80 l of chloroform was added to the 
samples, vortexed for 10 sec. and allowed to stand for 10 min. at room temperature. The 
resulting mixture was centrifuged at 12,000g for 15 min. at 4 C. At this step the mixture was 
separated into 3 phases: the protein containing red organic phase in the bottom, an interphase 
pellet containing DNA in the middle, and a colourless aqueous phase containing RNA at the 
top of the tube. 200 l of isopropanol was added to the separated aqueous phase. Samples 
were mixed well and allowed to stand for 10 min. at room temperature. RNA was pelleted by 
centrifugation at 12,000g for 10 min. at 4 C and washed with 80% ethanol (~1.5 ml). After 
vortexing, the samples were centrifuged at 7,500g for 5 min. at 4 C. Ethanol was poured out 
and the RNA pellet was resuspended in 10 l RNase free H2O. RNA concentration and purity 
of the preparation was determined by measuring absorbance at 260 and 280 nm. The optimal 




Reverse transcription was performed according to the method of Gerard and Alessio 
(1993). The reaction was carried out with 1 g of total RNA, 0.5 g oligo dT, 2 l of 10 mM 
dNTPs (1mM final concentration), 20 U RNase Inhibitor, 4 l 5X reaction buffer containing 
250mM Tris-HCl, 250mM KCl, 20mM MgCl2, 50mM ditiothreitol, 200U Reverse AidTMM-
MuLV reverse transcriptase (Fermentas). The final volume was made 20 l and incubated at 





Polymerase chain reaction was carried out with 0.2 l cDNA, 1 l 10X reaction buffer 
(250mM Tris-HCl, 250mM KCL), dNTP and MgCl2 with 0.2mM and 1.5mM final 
concentration, respectively, 5 pmol of each oligonucleotide and 1U Taq DNA Polymerase in a 
10 l final reaction volume. Reactions were performed in a Perkin Elmer Thermal Cycler. The 
amplification protocol comprised 30 cycles of 1 min at 94°C (denaturation), 30 s at 50°C 
(annealing) and 30 s at 72°C (extension). The first cycle was preceded by an extra 5 min at 
94°C and the final extension step was continued for 10 min. 
Primers pairs used for human -actin, human Fc RIIa and Fc RIIb1/b2 were as follows: 
 
Sense -actin : 5’-GGCTACAGCTTCACCACCAC-3’ 
Antisense -actin : 5’-GCGCTCAGGAGGAGCAATG-3’ 
Sense Fc RIIa: 5’-AGTGGCCTTGATCTACTGCA-3’ 
Antisense Fc RIIa: 5’-GAGTCATGTAGCCGCCGTCA-3’  
Sense Fc RIIb1/2: 5’-AGTGGCCTTGATCTACTGCA-3’ 
Antisense Fc RIIb 1/2: 5’-ATGTGGAACGGAAGAGCCTT-3’ 
The expected size of  PCR products are 400 bp for -actin, 157bp for Fc RIIa and 457/400 bp 




3.2.5. Level of circulating immunecomplexes (CIC) 
 
To measure IC present in plasma we used the CIC-C1q Enzyme Immunoassay, which 
is based on the principle that complement-fixing CIC will bind to immobilized human C1q 
protein. Plasma samples (diluted 1:50) and heat aggregated human gamma globulin, as 
standard were added to the C1q-coated microtiter wells and incubated for 60 minutes at room 
temperature. After washing (6x) with PBS containing 0.05% Tween-20TM, HRP-conjugated 
goat anti-human IgG was added to each test well and incubated for 30 minutes at 25oC. After 
washing, 2,2’-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) was used as a chromogen. OD 
values were measured at 405 nm. 
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3.2.6. Detection of antibody production by ELISA 
 
Supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA) for IgM 
and IgG production. Duplicate wells of ninety-six–well plates (Costar) were coated with 3 
μg/ml capture antibody reacting with the human immunoglobulin of interest, i.e.: polyclonal 
F(ab’)2 goat anti–human IgG and polyclonal F(ab)2 goat anti–human IgM at 4°C overnight. 
Plates were washed 3 times with PBS containing 0.1% Tween-20 and blocked with PBS 
containing 2% BSA. 50 l of B cell culture supernatants and - as negative control – medium 
RPMI alone were added to the wells and incubated for 1 hour at 37°C. Plates were again 
washed with PBS-Tween and HRP-conjugated detection antibody specific for human IgM and 
IgG (Dako) was added (1:2000 dilution) and incubated again for 1 hour at room temperature. 
Plates were again washed 6 times in PBS-Tween buffer, and developed with TMB substrate. 
Optical densities were read at 450nm. 
 
3.2.7. Enzyme-linked immunospot (ELISPOT) for detecting antibody secreting cells  
 
Ninety-six-well PVDF membrane plates (Millipore) were coated with 50 l 3 μg/ml 
human IgM and IgG specific antibodies at 4°C overnight. Plates were washed 3x with PBS, 
blocked with 200 l medium RPMI containing 10% FCS and incubated for two hours at room 
temperature. After washes, cells were added to the wells in triplicate at 3x105 cells per well in 
RPMI medium containing 10%FCS for 20 hours at 37°C in 5% CO2. Than cells were washed 
and the second HRPO-conjugated anti-IgM and anti-IgG antibodies were added to the plate 
for 90 minutes at 37°C. After removing the cells, the plates were washed 3x with PBS-Tween 
(0,5%). AEC (3-amino-9-ethyl carbazole) as chromogen substrate was added to the wells. 
Colour development was stopped by rinsing the plate with distilled water. After drying at 
room temperature, spots were counted using an ImmunoScan (CTL) reader. 
3.2.8. Proliferation assay 
Isolated B lymphocytes were cultured at 3 x 105 cells/well in 200 l medium RPMI 
containing 10% FCS (Gibco) in flat-bottom, 96-well microtiter plates (Costar), at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were stimulated with 3 g/ml F(ab')2 of goat 
anti-human IgM (Fc5 ) or anti-human IgG (Jackson) and cultured in the presence of various 
amounts of heat-aggregated C3 for 72h. Cells were pulsed with 1 Ci/well [3H]thymidine 
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(NEN, Boston, MA) for the last 16 h of culture. Incorporated radioactivity was measured 
using a Wallac 1409 liquid scintillation beta counter (Wallac, Allerod, Denmark). The results 
are expressed as mean cpm ± SEM of triplicate samples. 
 
3.2.9. Isolation of human C3, generation of C3b-like C3 
Human C3 was isolated from freshly drawn serum by fast protein liquid 
chromatography (FPLC) as described by Basta and Hammer. Purified C3 was concentrated, 
dialysed against PBS, followed by incubation with protein G beads (Pharmacia Biotech) to 
minimize the amount of contaminating IgG. The remaining IgG content was <1%, as assessed 
by ELISA. The purity of the C3 preparation was assessed by SDS-PAGE and Coomassie 
bluestaining. Aliquots were stored at -20°C and aggregated at 63°C for 20 min before use. 
Any possible toxic effect of various C3 preparations had been excluded by assessing the 
viability of treated cells, using trypan blue staining for microscopical and propidium iodide 
staining in FACS analysis. 
3.2.10. Plasmablast differentiation from memory B cells in vitro 
 
3×105 purified naive or memory B cells were cultured for 6 days in 200 l RPMI 
medium complemented with 10% FCS. Cells were activated with anti-IgM, anti-IgG 
antibodies (at 8 g/ml final concentration) and CpG (at 1 g/ml) in the presence of IL-2 
(50ng/ml) and IL-10 (50ng/ml) (Immunotools), respectively. The frequency of plasmablasts 
was measured by flow cytometry. 
 
 
3.2.11. Statistical analysis  
 
Data are expressed as mean ± SEM. Statistical significance of the difference between 
disease group and controls was determined using Mann-Whitney U test. Multiple group 
analyses were performed using one-way ANOVA with Kruskall–Wallis test. Correlation 
coefficients were calculated using Spearman’s rank correlation. Data were analysed by Prism 






4.1. Flow-cytometric analysis of IC-binding receptors expressed on human B cell of 
healthy controls and SLE patients 
 
 
4.1.1. Surface expression of Fc - and complement receptors on peripheral B cells of 
healthy controls and SLE patients  
Cells isolated from 15 patients diagnosed with inactive, 8 with active SLE according 
to the SLEDAI and 30 healthy controls were investigated by flow cytometry. Peripheral B 
cells were identified by gating forward and side scatter profiles and CD19-positivity. Relative 
fluorescence intensity (RFI) of the samples was calculated as described in the section of 
Materials and Methods. As shown in Figure 5, despite individual variations there was a 
significant decrease in the expression of IC-binding receptors on B cells of SLE patients 
compared to the normal controls. CR1 expression on B cells from SLE patients with active 
disease (SLEDAI>10) was significantly lower  (median 16,4; 25th to 75th percentile, 14,8 to 
21,5) compared to healthy controls (median 37; 25th to 75th percentile, 32,5 to 43; P<0,001) 
or patients with inactive SLE (median 32; 25th to 75th percentile, 25,8 to 36; P<0,05). 
Reduction in Fc RII expression was also more pronounced in patients with active SLE 
(median 32,6; 25th to 75th percentile, 29 to 36,7) compared with age-matched controls 
(median 63,5; 25th to 75th percentile, 55,3 to 67,5; P<0,001) or patients with inactive SLE 
(median 53; 25th to 75th percentile, 43,1 to 64; P<0,05). CR2 expression was also reduced in 
patients with SLE (median 5,7; 25th to 75th percentile, 3,7 to 6,5) compared to controls 
(median 6,5; 25th to 75th percentile, 5,8 to 7,8; P<0,01), however, there was no statistically 
significant difference between patients with active or inactive disease (data not shown). 
Patients with SLE segregated into groups expressing CR2 at lower and higher level, 
irrespective of the disease activity. We next analyzed the possible correlation of changes with 
























































































































































Figure 5. Surface expression of Fc - and complement receptors on peripheral B cells of 
SLE patients and healthy controls 
Blood mononuclear cells (BMC) isolated from individual patients and healthy volunteers 
were stained with specific antibodies against CR1, CR2 and Fc RII. B cells were analyzed 
selectively by gating forward and side scatter profiles and CD19-positivity. Relative 
fluorescence intensity (RFI) was obtained by dividing the mean fluorescence intensity (MFI) 
of the sample with that of the isotype–matched control. RFIs are given for Fc RII (A) CR1 
(B) and CR2(C) expression. Differences between donor groups were compared using the 















4.1.2. Patients with active SLE display disturbed ratio of various B cell subpopulations  
 
 
Lymphocyte counts are known to be significantly decreased in SLE, and lymphopenia 
is the most prevalent initial laboratory abnormality in this disease. The first report of disturbed 
peripheral B lymphocyte homeostasis in SLE demonstrated that the frequencies of CD27+ B 
cells were significantly enhanced, mainly in patients with active SLE. As shown in Figure 6, 
we found that patients with SLE have a disturbed ratio of CD27- naïve and CD27+ memory B 
cells (53% - 47%) compared to healthy individuals (75% - 25%). Circulating memory B cells 
express either IgM or secondary antibody isotypes and are distinguished from naive B cells by 
the appearance of cell surface CD27. As Figure 6 illustrates we observed a striking reduction 
in the ratio of IgM memory compartment, and in the same time a large expansion of CD27high 






















Figure 6. The ratio of IgM+/CD27+ unswitched memory B cells are greatly reduced in 
active SLE 
Blood mononuclear cells (BMC) isolated from individual patients and controls were stained 
with specific antibody and analyzed. Density plot of gated CD19+ B cells is shown, double-
stained with the following antibodies: PE-labelled anti-CD27, Cy5-labelled anti-IgM F(ab’)2 
as indicated. Circles emphasize major differences in the ratio of CD27+/sIgM+ memory B 



































Figure 7. Increased frequency of the CD27high/sIglow plasmablasts population in active 
SLE 
Density plot of gated CD19+ B cells is shown, triple-stained with the following antibodies: 
PE-labelled anti-CD27, Cy5-labelled anti-IgM F(ab’)2 and FITC-labelled anti-CD32 as 
indicated. Ig-isotype matched FITC- and PE-conjugated mouse antibodies were used as 
negative controls for non-specific staining. Circles emphasize major differences in the ratio of 
CD27high/sIglow plasmablasts. Data shown are representative of six independent experiments.  
 
 
4.1.3. IgM+/CD27+ and IgM-/CD27+ memory cells from SLE patients fail to up-regulate 
the inhibitory Fc RII  
 
Investigating Fc RII expression on CD19+ B cells isolated from patients with SLE a 
striking decrease was found compared to the controls. This reduction was more pronounced in 
the group of patients with active disease. Since it has been shown that Fc RII expression on B 
cells is changing during maturation, in further studies we aimed to clarify which B cell 
subpopulations are affected. CD19+ peripheral B cells were divided into four groups based on 
their expression of CD27: IgM+/CD27- naïve, IgM+/CD27+ and IgM-/CD27+ memory cells 
and CD27high plasmablasts. While non-autoimmune individuals displayed an increased level of 
Fc RII expression on memory cells compared to naïve cells, memory B cells from SLE failed 
to up-regulate this receptor (Figure 8.). Comparing IgM+ and switched memory cells from 
healthy individuals, the former ones showed higher Fc RII expression (Figure 8/A.). The 
reduced Fc RII expression found in SLE affected both IgM+ and switched memory cells, to 
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somewhat higher extent the latter (Figure 8/C). Interestingly, the pattern of Fc RII expression 
on IgM+ memory cells was different from that on switched memory cells from healthy 
donors; namely, the expression range was much wider in the latter case. In SLE both IgM- and 
IgM+ cells displayed a wide Fc RII expression range.  
As seen in Figure 8/C the expression level of Fc RII was almost the same on the 
CD27- naive B cell population in both SLE patients and healthy individuals. In contrast to 
this, CD27+ memory B cells from the autoimmune patients had significantly lower surface 
levels of Fc RII than the healthy controls (Figure 8/C), most probably due to a failure to up-
regulate Fc RII expression as B cells become memory cells.  
Although the Fc RII monoclonal antibody (clone FL18.26) we used can not 
distinguish activating Fc RIIa and inhibitory Fc RIIb isoforms, we found that the mRNA 
level of Fc RIIa in peripheral B cells was below the limit of detection (see detailes in 4.1.8.), 


















































Figure 8. Fc RII expression on naïve and memory B cells of healthy individuals and SLE 
patients 
Flow cytometric analysis of gated CD19+ B cells, triple-stained with the following antibodies: 
FITC-labelled anti-CD32, PE-labelled anti-CD27 and Cy5-labelled anti-IgM. Ig-isotype 
matched FITC- and PE conjugated mouse antibodies were used as negative controls for non-
specific staining.  
(A) The expression of Fc RII on IgM+ (dotted line) and IgM- (dashed line) CD27+ memory B 
cells of healthy controls compared to naïve cells (solid line). Histogram of one representative 
experiment is shown. (B) The expression of Fc RII on IgM+ (dotted line) and  IgM- (dashed 
line) memory B cells of SLE patients compared to naïve cells (solid line). Histogram of one 
representative experiment is shown. (C) Average MFI-values of 8 samples treated as 
described above. Open columns: CD27- IgM+ cells, grey columns: CD27+ IgM+ cells, black 
comuns CD27+ IgM- cells of healthy control individuals and SLE patients, as indicated. Data 
are expressed as mean ± SE. (Mann –Whitney U test P <0.01) 
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4.1.4. Distinct pattern of CR1 and CR2 expression on CD27- naive and CD27+ memory B 
cells of healthy donors and SLE patients 
 
 
The reduced level of CR1 on erythrocytes is considered a key feature contributing to 
IC overload and exaggerated complement activation in SLE. Comparatively fewer studies 
documented lower levels of CR1 on leukocytes in this disease. The decline in erythrocyte 
CR1 is considered an acquired phenomenon caused by the proteolytic cleavage of CR1 from 
the membrane of erythrocytes. The mechanism underlying reduced CR1 expression on 
nucleated cells is not yet known and is under constant investigation. 
In studies using lupus prone MRL/lpr and female (NZB X NZW) F1mice it had been 
shown that the level of complement receptors CR1/2 is strongly reduced on B lymphocytes. In 
the former model, CRl/CR2 levels were found to be decreased from an early time point, 
before nephritis and elevated levels of autoantibodies appear, indicating the relevance of these 
receptors in autoimmunity.  
In contrast to mice in humans, where CR1 and CR2 are encoded by distinct genes and 
thus have different functions, the expression level of these receptors on distinct B cell 
subpopulations has not been defined so far, not even in healthy individuals. 
We found that the level of CR1 was higher on CD27+ memory B cells compared to 
CD27- naïve cells in healthy donors (Figure 9/A) - similarly to the expression of Fc RII. In 
contrast to Fc RII levels, there was not, however, any difference between IgM+ and switched 
memory compartment (Figure 9/A). In contrast to Fc RII and CR1, the expression of CR2 
was at the same level both on CD27- naïve and CD27+ memory cells and no up-regulation 
could be seen in the control group, reflecting again differences in the regulation and function 
of human CR1 and CR2 (Figure 10/A).  
Investigating CR1 and CR2 expression on CD19+ B cells isolated from patients with 
SLE, a significant decrease of both receptors was found, however different subpopulations 
were affected. While a reduced CR1 level could be measured only on CD27+ memory cells 
(Figure 9/C), a lower CR2 expression was characteristic for both the CD27- naïve and CD27+ 
memory cells (Figure 10/C). In the case of CR1-expression both IgM+ and switched memory 











































Figure 9. CR1 expression on naïve and memory B cells of healthy individuals and SLE 
patients 
Flow cytometric analysis of gated CD19+ B cells, triple-stained with the following antibodies: 
FITC-labelled anti-CD35, PE-labelled anti-CD27 and Cy5-labelled anti-IgM. Ig-isotype 
matched FITC- and PE conjugated mouse antibodies were used as negative controls for non-
specific staining.  
(A) The expression of CR1 on IgM+ (dotted line) and IgM- (dashed line) CD27+ memory B 
cells of healthy controls compared to naïve cells (solid line). Histogram of one representative 
experiment is shown. (B) The expression of CR1 on IgM+ (dotted line) and IgM- (dashed line) 
memory B cells of SLE patients compared to naïve cells (solid line). Histogram of one 
representative experiment is shown. (C) Average MFI-values of 8 samples treated as 
described above. Open columns: CD27- IgM+ cells, grey columns: CD27+ IgM+ cells, black 
comuns CD27+ IgM- cells of healthy control individuals and SLE patients, as indicated. Data 












































Figure 10. CR2 expression on naïve and memory B cells of healthy individuals and SLE 
patients 
Flow cytometric analysis of gated CD19+ B cells, triple-stained with the following antibodies: 
FITC-labelled anti-CD21, PE-labelled anti-CD27 and Cy5-labelled anti-IgM. Ig-isotype 
matched FITC- and PE conjugated mouse antibodies were used as negative controls for non-
specific staining.  
(A) The expression of CR2 on IgM+ (dotted line) and IgM- (dashed line) CD27+ memory B 
cells of healthy controls compared to naïve cells (solid line). Histogram of one representative 
experiment is shown. (B) The expression of CR2 on IgM+ (dotted line) and IgM- (dashed line) 
memory B cells of SLE patients compared to naïve cells (solid line). Histogram of one 
representative experiment is shown. (C) Average MFI-values of 6 samples treated as 
described above. Open columns: CD27- IgM+ cells, grey columns: CD27+ IgM+ cells, black 
comuns CD27+ IgM- cells of healthy control individuals and SLE patients, as indicated. Data 
are expressed as mean ± SE. (Mann –Whitney U test P <0.01) 
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4.1.5. IgM+/CD27+ and IgG+/CD27+ memory cells of SLE patients express lower sIg 
levels than B cells of healthy donors 
 
Comparing sIg expression on CD27-/IgM+ naïve B cells and CD27+/IgM+ memory 
cells from healthy individuals, a significantly higher level could be detected on the latter 
(Table I.). The difference between CD27- naïve and CD27+ memory B cells was not observed 
in the SLE group. CD27-/IgM+ naïve B cells of SLE patients expressed higher sIgM levels 
than that of the healthy donors. Since naïve and transitional B cells present in the CD27- 
compartment were not investigated separately, a higher frequency of transitional B cells 
expressing higher sIgM-levels in SLE may lie behind this phenomenon. Investigating sIg 
expression we found a decrease on both IgM+/CD27+ and IgG+/CD27+ memory B cells of 




  CD27- CD27+
sIgM expression (MFI)   
Control (n=8) 338 ± 59 a b 1404 ± 139 a c
SLE (n=8) 767 ± 118 b 746 ±71 c
sIgG expression (MFI)   
Control (n=8) - 1173 ± 99 d













Table I.  
Surface Ig expression on CD27- naïve and CD27+ memory B cells of healthy individuals 
and SLE patients 
MFI: mean fluorescence intensity. Data are presented as mean ± SE. 
a,b,c : p< 0.01;  d: p < 0.05  
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4.1.6. CD19+/CD27high/sIglow plasmablasts of healthy donors and SLE patients express 
minimal levels of Fc RII and CR1 
 
The terminally differentiated CD19+/CD27high/sIglow B cell population displays very 
low levels of Fc RII and CR1. All of the control individuals showed also minimal levels of 
these receptors on their plasmablasts. A typical FACS profile of Fc RII and CR1 expression 























































Figure 11. Fc RII and CR1 expression on CD19+/CD27high/sIglow plasmablasts of healthy 
donors and SLE patients  
Dot plot of gated CD19+ B cells, triple-stained with the following antibodies: PE-labelled 
anti-CD27, Cy5-labelled anti-IgM F(ab’)2 and FITC-labelled anti-CD32 or FITC-labelled 
anti-CD35, as indicated. Ig-isotype matched FITC- and PE-conjugated mouse antibodies were 
used as negative controls for non-specific staining. The upper two dot-plots show data 
obtained after staining for Fc RII on cells of a healthy, control individual and an SLE patient. 
The lower two dot-plots show data obtained after staining for CR1 on cells of a healthy, 
control individual and an SLE patient. Major differences in the ratio of CD27high/sIglow 
plasmablasts are emphasized by circles. Data shown are representative of 6 independent 
experiments.  
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4.1.7. Longitudinal study of the expression of IC-binding receptors on B cells of SLE 
patients and healthy donors 
 
Genetically determined alterations in receptor expression are expected to be relatively 
stable over time. To test whether the reduced expression of IC-binding receptors on B cells 
from SLE patients changes over a two-year period, we repeated flow cytometric 
measurements 1 and 2 years after the first study in 3 patients with SLEDAI > 10. As shown in 
figure 12, the inhibitory receptors Fc RII and CR1 showed less stability during the tested 


















































































































Figure 12. Follow –up analysis of Fc RII, CR1 and CR2 expression on peripheral B cells 
of three patient with SLE 
Blood mononuclear cells (BMC) isolated from three patients with SLE (dots) and four 
healthy controls (boxes) were monitored repeatedly. Cells were stained with specific antibody 
against CR1, CR2 and Fc RII. B cells were analyzed selectively by gating forward and side 
scatter profiles and CD19-positivity. Relative fluorescence intensity (RFI) was obtained by 
dividing the mean fluorescence intensity (MFI) of the sample with that for the isotype–
matched control.  The upper and lower limits of the boxes represent the 75th and 25th 
percentile, respectively. The line inside the boxes indicates the median. 
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4.1.8. Expression profile of Fc RII in B cells at mRNA level 
 
To confirm the expression profile of Fc RII in B cells from healthy controls and SLE 
patients, we performed semiquantitative RT-PCR to detect the message for the inhibitory 
Fc RIIb1/b2 and activating Fc RIIa isoform, using MACS-purified CD19+ B cells. The 
inhibitory Fc RIIb has two major splice variants, IIb1 and IIb2. An important functional 
difference is that Fc RIIb2 lacks the 19 aminoacids of the first exon encoding the cytoplasmic 
domain and is more capable of endocytosis. PCR primers for Fc RIIb were designed to 
amplify both IIb1 and IIb2 messages with amplicons distinguishable on the basis of size. The 
specificity of the primers and PCR were confirmed by PCR using Fc RIIb1, Fc RIIb2-
containing plasmids as the template (data not shown). In agreement with previous data, 
CD19+ B cells express more IIb1 message than IIb2 (13/A) and in contrast to myeloid cells, 
do not express detectable IIa isoform (13/C). In the B cells of SLE patients we could only 
detect the IIb1 isoform (13/B). 
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Figure 13. Comparison of Fc RIIb1/2 and Fc RIIa mRNA expression pattern in B cells 
from healthy controls and patients with SLE 
Total RNA from MACS-purified CD19+ peripheral B cells from healthy donors and SLE 
patients was isolated and used for RT-PCR. Amplification of -actin served to check RNA 
amounts loaded on the agarose gel. PCR products were electrophoresed on 2% agarose gel 
and stained with ethidium bromide. 7 samples of healthy donors (A) and 6 samples of SLE 
patients (B) for Fc RII are shown. 2 samples of healthy and 6 samples of SLE patients for 
Fc RIIa (C) are shown. Raji cells and monocytes were used as positive control. 
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4.1.9. There is no correlation between the reduced expression of IC-binding receptors 
and serum IC concentrations in SLE patients 
 
Each SLE patient may present different combinations of pathological manifestations 
and serum factors. However, IC overload is a universal feature of this disease. Measurement 
of the concentration of IC provides a more sensitive index of disease activity than either 
serum C3 or C4 concentrations, though C1q containing IC represents only a limited species of 
complexes. Since ligand-induced down-regulation of Fc - and complement receptors is a 
feasible scenario that may happen in SLE, we tested whether complement containing immune 
complexes (CIC), as ligands, may lie behind the reduction in receptor density found in this 
case. We set out to investigate if there is a correlation between C1q binding circulating IC 
levels and receptor expression. As expected, we found significantly (P<0.01) higher levels of 
CIC in the sera of SLE patients as compared to that of healthy controls (Figure14). However, 
we could not observe consistent correlations between CIC concentration and surface density 























































4.1.10. Culturing on immobilized C3b prevents CR1 up-regulation on memory B cells 
 
 
Next, we wanted to reveal whether CR1 clustering has any modulatory effect on CR1 
expression. To this end we incubated the B cells on surfaces coated with purified C3b and 
assessed CR1 expression in different B cell subpopulations 16 hours later. We found, that the 
immobilized natural ligand of CR1, offered in a cross-linked form, had no effect on CR1 
expression in the naïve B cell population, but induced the loss of up-regulation of the receptor 
on memory B cells. This effect is not associated with a general down-modulation of 
membrane antigens, as we could not observe any changes in the expression of other receptors 
such as Fc RII and CD19. As illustrated in Figure 15/C the decrease of CR1 is selectively 
induced by immobilized C3b, since treating the cells with soluble C3 had no such effect. The 
fact that CR1 clustering is able to induce receptor down-modulation selectively on memory B 
cells in a similar manner what we observed in SLE patients, suggests that CR1 expression 


























Figure 15. The effect of immobilized and soluble C3b on CR1 expression
Purified mononuclear cells from healthy donors were cultured in the absence (A) or in the 
presence (B) of immobilized C3b (Calbiochem) overnight. Histogram C shows the effect of 
soluble C3b on CR1 expression. After incubation, CR1 expression on naïve and memory B 
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cells was measured by flow cytometry. Analysis of gated CD19+ B cells was performed after 
staining the cells with the following antibodies: FITC-labelled anti-CD35, PE-labelled anti-
CD27. Ig-isotype matched FITC- and PE conjugated mouse antibodies were used as negative 
controls for non-specific staining. One representative experiment of three is shown. 
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4.2. Functional consequences of CR1 clustering on antigen-dependent and antigen-
independent activation of B cells 
 
4.2.1. Naïve B cells are more sensitive to CR1 induced inhibition of BCR triggered 
proliferation than memory B cells  
 
It has been earlier shown by our group that ligand-binding to CR1 - in contrast to CR2 
- inhibits BCR-induced proliferation of human B cells. In our present experiment purified 
CD19+ B cells were divided into two groups based on their expression-levels of CD27 as a 
typical marker for mutated memory B cells. CD27- naïve B cells were activated with 10 g/ml 
of goat anti-human IgM F(ab’)2,  while CD27+ memory B cells  with 10 g/ml of goat anti-
human IgM F(ab’)2 and IgG F(ab’)2, respectively. As it has been shown that human C3 in 
aggregated form behaves as C3b-like C3 and reacts preferentially with CR1 on B 
lymphocytes, first we tested which concentration of aggregated C3 would be optimal in the 
case of our present culture conditions (Fig. 16, panel A). Based on these results, separated 
naïve and memory B cells were cultured in the presence of 20 g/ml aggregated C3 for 72 h. 
As shown in panel B of Figure 16 the multimeric CR1 ligand exerts an inhibition on the BCR-
induced proliferation in the case of both subpopulation, the degree of inhibition, however, was 
different between the naïve and memory cell-compartment. While the inhibitory capacity of 
aggregated C3 was quite similar on IgM+ and IgG+ memory cells, on naïve cells higher 
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Figure 16. Inhibition of naïve and memory B cell proliferation by aggregated C3  
Purified CD19+ B cells were separated into CD27- and CD27+ cells. (A) CD27- naïve cells 
were activated with 10 g/ml goat anti-human IgM F(ab’)2 and cultured in the absence or  
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presence of various amounts of aggregated C3 (ranging between 5-20 g/ml.) (B) Naïve and 
memory B cells were activated with10 g/ml of goat anti-human IgM F(ab’)2 and anti-human 
IgG F(ab’)2 respectively, and cultured in the presence of aggregated C3 at the concentration of 
20 g/ml. 3H-thymidin incorporation was measured after 72h. Data are presented as inhibition 
(%) of activation. Columns represent the mean SEM of triplicate samples. One representative 
experiment of three is shown. 
 
4.2.2. Lower levels of CR1 on B cells from SLE patients do not influence their BCR-
induced proliferation 
 
As we found that up to 50% of CR1 and Fc RII is lost from the surface of memory B 
cells of active SLE patients, we investigated whether this reduction results any in change in 
the inhibitory capacity of CR1 on the BCR-induced B cell proliferation. Because only very 
low amounts of blood could be obtaiend from SLE patients (25-30 ml), not enough B cells 
could be isolated to investigate naïve and memory cells separately. This is why we used 
unseparated B cells to test whether the decreased CR1 density on B cells has any impact on 
BCR-induced proliferation. B cells were activated with 10 g/ml of goat anti-human IgM/IgG 
F(ab’)2 and cultured in the presence of various amounts of aggregated C3 for 72 h. As 
illustrated by Figure 12 the highest concentration of the ligand (20 g/ml) strongly inhibits 
BCR-induced proliferation. The degree of this inhibition is similar to that found using naïve B 
cell population of healthy donors ( 80%, Fig.17.).  
These data suggest that although there is a significant reduction in CR1 density on B 
cells of SLE patients, this does not affect their inhibitory capacity - the cells respond to the 
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Figure 17. The effect of CR1 clustering on BCR- induced proliferation of lymphocytes 
from SLE patients 
Purified CD19+ peripheral B cells were activated with 10 g/ml goat anti-human IgM F(ab’)2 
and cultured in the absence or  presence of various amounts of aggregated C3 (ranging 
between 5-20 g/ml.) 3H-thymidin incorporation was measured after 72h. Data are presented 
as inhibition (%) of activation. Columns represent the mean SEM of triplicate samples. One 




4.2.3. CR1 ligation does not affect the BCR-induced plasmablast formation of memory B 
cells 
 Because IL-2 and IL-10 have been reported to induce peripheral memory B cells to 
differentiate into antibody secreting cells (ASC) in vitro, we were interested in determining 
the rate of differentiation in distinct subsets of human B cells. Purified B lymphocytes were 
separated into CD27- and CD27+ fractions. Following stimulation for 6 days with IL-10 and 
IL-2, CD27- naive B cells yielded <1% CD27high/sIglow ASC, irrespective of whether anti-IgM 
F(ab)’2 was present or not. In contrast, we could detect approximately 6% of CD27high/sIglow 
cells in cultures of memory B cells stimulated with IL-2/IL-10 alone. When anti-IgM F(ab)’2 
and anti-IgG F(ab)’2 antibodies were also present in the culture, the frequency of 
CD27high/sIglow plasmablasts increased up to 15-18%. We next questioned whether adding 
aggregated C3 to the culture could influence plasmablast formation from memory B cells 
induced by BCR/IL-2/IL-10 stimulus. As illustrated in Figure 18, we could not detect any 
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effect of CR1 clustering on differentiation. In vitro activated naïve and memory B cells were 
harvested after 6 days of culture and then were incubated with PE-anti-CD27 and FITC-anti-
IgM/IgG antibodies for cytometric analysis. The generation of functional ASC was assessed 
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Figure 18. Generation of sIglow/CD27high plasmablasts from memory B cells upon BCR 
stimulus in healthy donors  
Separated memory B cells were cultured in medium alone; anti-IgM (10 g/ml) (A) or anti-
IgG (B); IL-10 (50ng/ml)/IL-2(50ng/ml ) and anti-IgM or IgG (10 g/ml) /IL-10 
(50ng/ml)/IL-2(50ng/ml) in the presence or absence of aggregated C3 (20 g/ml) at a final cell 
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density of 3 105per well for 6 days. The percentage of CD27high/sIglow plasmablasts was 
measured by flow cytometry.  Analysis of gated CD19+ B cells was performed after staining 
the cells with the following antibodies: FITC-labelled anti-IgG/IgM, PE-labelled anti-CD27. 
Ig-isotype matched FITC- and PE conjugated mouse antibodies were used as negative 
controls for non-specific staining. One representative experiment of three is shown. 
 
 
4.2.4. CR1 aggregation has no effect on CpG induced proliferation of CD27- naïve and 
CD27+ memory B cells from healthy donors 
 
Naïve and memory B cells were isolated from blood by sorting for expression of 
CD27. First we tested the capacity of isolated subpopulations to proliferate in response to 
CpG. Naïve and memory B cells were activated with 1 g/ml of CpG oligodeoxynucleotides 
and cultured in the presence of various amounts of aggregated C3 (ranging between 5-
20 g/ml) for 72 h. As illustrated in Figure 19 CpG-induced proliferation in both the naïve and 
memory B cell population. Cluestering CR1, by aggregated C3 did not influence the CpG-











































































Figure 19. CR1 clustering has no effect on CpG induced proliferation of CD27- naïve 
and CD27+ memory B cells from healthy donors 
Purified CD19+ peripheral B cells were separated into CD27- and CD27+ cells. CD27-naïve 
(A) and CD27- memory cells (B) were activated with 1 g/ml CpG oligodeoxynucleotides 
and cultured in the absence or presence of various amounts of aggregated C3 (ranging 
between 5-20 g/ml). 3H-thymidin incorporation was measured after 72h. Data are presented 
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as stimulation index. Columns represent the mean SEM of triplicate samples. 
Onrepresentative experiments of three is shown. 
 
 
4.2.5. CR1 clustering has no influence on CpG induced plasma-cell differentiation of 
memory B cells in vitro  
 
Antigen-independent activation of B cells is thought to be one of the mechanisms 
responsible for antibody-mediated autoimmunity, as seen in SLE and other autoimmune 
diseases. Some investigators have hypothesized that an absolute requirement to activate naive 
B cells via BCR would allow proper self/non–self-discrimination at this developmental stage 
and prevent the emergence of autoreactive plasma cells via polyclonal antigen-independent B-
cell activation. In contrast, TLR-9 activation of CD27+ memory B cells by unmethylated CpG 
DNA may be a homeostatic mechanism that maintains adaptive long-term B-cell memory in 
the absence of antigen. In agreement with others we observed only a small extent of 
plasmablast induction in the CD27- naïve population upon CpG stimulus. However, 
predominant differentiation into plasma cells occurred in the CD27+ B fraction, as illustrated 
in Figure 20 The relative frequency of CD27high/sIglow plasmablasts increased up to 30% after 
CpG stimulus. Plasmablasts were defined by the CD27high/sIglow phenotype.  
Next we investigated whether aggregated C3, applied for CR1 clustering on the cell 
surface, influences the plasmablast differentiation from memory cells. As shown in Figure 20 
the presence of the CR1 ligand had no effect on the differentiation. It has been reported that 
IL-10 rapidly up-regulates TLR-9 in memory B cells. In order to test whether IL-10 has a 
synergistic effect on CpG-induced plasmablast formation, we added IL-10 to the culture. 
Under these conditions, we found a slight increase in the frequency of plasmablasts compared 














































































Figure 20. Generation of sIglow/CD27high plasma cells from CD27+ memory B cells of 
healthy donors upon CpG stimulus 
Separated CD27+ memory B cells were cultured in medium, CpG (1 g/ml), CpG + IL-10 
(50ng/ml) in the presence or absence of aggregated C3 (20 g/ml) at a final cell density of 
3 105 per well for 6 days. The cells were then stained with anti-IgM/IgG-FITC and anti-
CD27-PE. The relative percentages of CD27high-positive cells are shown. The error bars 
represent the mean  SEM of duplicate samples. 
 
4.2.6. CpG-mediated plasmablast formation of CD27+ memory B cells is accompanied by 
an increased number of IgM but not IgG secreting cells; B cells from SLE patients fail to 
differentiate into IgM secreting plasmablasts upon induction by CpG 
 
We found that CD27+ memory B cells from healthy donors are able to differentiate to 
CD27high/sIglow plasmablasts upon CpG stimulation, as measured by flow cytometry. We used 
ELISPOT to assess the generation of functional antibody secreting cells (ASC) by 
determining the frequency of cells secreting IgM, and IgGs. After removing monocytes by 
plastic adherence isolated mononuclear cells were incubated for 6 days in the presence of 
CpG. As shown in Figure 21, CpG-mediated plasmablast formation of CD27+ memory B cells 
was accompanied by an increased number of IgM but not IgG secreting cells, indicative of 
plasma-cell formation in the IgM memory compartment. Similarly to our flow cytometric 
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result, aggregated C3 had no impact on the differentiation of functionally active antibody 
forming cells. 
Isolated mononuclear cells from SLE patients were also incubated for 6 days in the 
presence of CpG and were sorted directly into ELISPOT plates previously coated with anti-
human IgM and IgG antibodies. The number of cells secreting IgM and IgG was determined. 
While in healthy individuals, we could detect IgM producing cells after CpG stimulus, B cells 
from SLE patients failed to form IgM secreting plasmablasts under the same conditions, as 
shown in Figure 21. It also has to be mentioned that BCR stimulation could not overcome the 
proliferative defect (data not shown). 
Next, we investigated the effect of CpG on the spontaneous IgG production by B cells of SLE 
patients. As seen in Figure 21 spontaneous IgG production was not influenced by CpG and 
most probably not any IgG-producing plasmablasts were generated during culture. 
Aggregated C3 had any effect neither on spontaneous IgG secretion nor on formation of IgG–
producing plasmablats by B cells from SLE patients upon CpG stimulus. As SLE patients 
have high frequency of autoreactive, ssDNA specific B cells, CpG is able to engage surface 
IgG and TLR-9 simultaneously. Co-engagement of these receptors however, did not result in 
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Figure 21. CpG-mediated formation of antibody secreting cells in healthy donors and 
patients with SLE 
Isolated peripheral mononuclear cells from healthy donors and SLE patients with active 
disease were cultured with CpG ODN for 6 days in the presence or absence of aggregated C3 
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(20 g/ml). Cells were then transferred into wells previously coated with either polyclonal 
anti-human IgM or anti-human IgG antibody and cultured overnight. Columns show the total 
number of IgM and IgG producing B cells/4x105 BMC. The error bars represent the mean











It is widely accepted that dysfunctions of Fc , complement- and B-cell antigen 
receptors contribute to the initiation and/or maintenance of IC-mediated autoimmune 
disorders (34;39;117-119). Control of cognate interactions and inflammatory responses, IC-
clearance, B cell selection and activation may all be affected by altered expression or function 
of these receptors. Various censoring mechanisms, including anergy and sequestration prevent 
the participation of mature autoreactive B cells in germinal center reactions, thereby avoiding 
their expansion into memory and plasma cells. Several studies suggest that IC-binding 
receptors play a crucial role at checkpoints responsible for avoiding autoimmunity (120-123). 
As shown in Figure 22, depending on the composition of IC and the degradation stage 
of complement components C3 and C4 in the complex, IC-binding receptors may influence 
the fate of autoreactive B cells in distinct ways. Fc RIIb co-crosslinked with BCR regulates B 
cell activation negatively. Similarly, human CR1 clustered by multimeric C3b on BCR-
activated human B lymphocytes has also been shown to induce negative regulatory signals, a 
phenomenon demonstrated recently on human T cells, as well (67). On the other hand CR2, 
which interacts with C3d, the final cleavage product of C3 has been described as a molecular 
adjuvant, which lowers the threshold of B cell activation by cross-linking CR2 to surface Ig 
both on human and murine cells (124). 
 
 
Figure 22. Regulation of B cell activation by IC binding receptors (Erdei et al., 2003) 
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Failed up-regulation of inhibitory Fc RIIb and CR1 on memory B cells from SLE patients 
Human B cells express various Fc RII isoforms at different ratios in resting state and 
during their activation. Their appearance is highly regulated by various stimulatory signals 
(125-127). Activation of human B cells results in enhanced Fc RII expression on the cell 
surface accompanied by the up-regulation of the b1 and the concomitant down-modulation of 
b2 isoform (128). Expression of Fc RIIB is typically upregulated on activated B cells in mice, 
too. Autoimmune mouse strains lack this upregulation through polymorphisms in the 
promoter of Fcgr2b (129-131). Restoring upregulation of Fc RIIB on activated B cells in 
autoimmune strains is sufficient to block IgG anti-DNA accumulation and the development of 
autoimmune disease in these strains (132). Regarding a possible role of modulating CR1 
expression on human B cells similar to this, there is no documented evidence in the literature 
so far.
We carried out a phenotypic analysis of the expression of IC-binding receptors on B 
cells taken from healthy individuals and SLE patients. Despite of individual variations there 
was a significant decrease in the expression of these receptors on B cells of SLE patients 
compared to the normal controls. CR1 expression on B cells from SLE patients with active 
disease (SLEDAI>10) was significantly lower compared to healthy controls or patients with 
inactive SLE. Reduction in Fc RII expression was also more pronounced in patients with 
active SLE compared with age-matched controls or patients with inactive SLE. We observed a 
positive correlation between the expression of Fc RII and CR1, indicating that these 
inhibitory receptors are simultaneously down-modulated. We found that the reduced 
expression of Fc RII and CR1 on B cells from SLE patients was unstable over a two-year 
period. This finding indicates that the reduced expression of these receptors associated with 
down-regulating mechanisms specifically related to the disease process rather than to primary 
defects predisposing the individual to the disease. 
Distribution of these receptors on distinct B cell subpopulations in the blood has not 
been documented in detail so far, not even in healthy individuals. In our studies SLE patients 
with reduced number of IC-binding receptors on CD19+ B cells were selected and further 
examined in detail to reveal whether the previously found reduction affects certain B cell 
subpopulations. We are convinced that investigation of the naïve, IgM+ and switched memory 
B cell compartment might provide further insights into knowledge of the relevance of IC-
binding receptors at the late stage of B cell maturation in both physiological and pathological 
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conditions. We found that the expression of the inhibitory receptors Fc RII and CR1 is 
significantly up-regulated on the memory B cells of healthy controls; however their 
expression is considerably decreased on memory B cells of SLE patients, reaching the levels 
of receptor density found on naive cells. 
Immunological memory protects host organisms from recurrent infections. Memory 
responses are faster, larger, and qualitatively different from primary responses. It is however, 
unclear what the exact requirements are for maintaining the ability to make such a response 
(100;133). Many factors can affect the development and survival of memory lymphocytes. It 
has long been proposed that Ag in the form of IC deposited on the surface of follicular 
dendritic cells via complement receptors and Fc Rs is necessary for the maintenance of 
memory B cells and secondary responses (42;134;135). In this manner, up-regulation of the 
inhibitory CR1 and Fc RII on memory cells may have a role in the sensitivity of their 
response to antigen recall under physiological conditions. The observed loss of this up-
regulation in SLE patients may have a strong influence on the memory response and 
differentiation into antibody secreting plasma cells. 
 
The expression pattern of the enhancing co-receptor CR2 is different from that of the 
inhibitory receptors 
While CR1 expressed on mouse B cells have a similar role as CR2, in humans, where 
CR1 and CR2 are encoded by different genes, they have been shown recently to exert distinct 
functions. Regarding the role of CR2 in B cell activation probably its most important function 
is to promote B cell activation by lowering the signaling threshold of BCR. In our studies, 
regarding the expression of CR2, the co-receptor for BCR, no difference was found between 
naive and memory cells of healthy individuals – in contrast to Fc RII and CR1. In SLE 
however, a reduced expression of CR2 was characteristic for both the naive and memory 
cells. These findings further strengthen the notion that CR1 and CR2 expression is 
differentially regulated on human B lymphocytes under physiological conditions as well as in 
SLE. Taking into consideration that these two complement receptors have opposite effects on 
human B cells, their differential expression can be considered as an important regulatory 
component of B cell function. 
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The loss of up-regulation of Fc RII and CR1 observed in SLE affects both IgM+ and switched 
memory B cells 
 
To get a further insight into which memory B-cell population is affected in SLE, we 
examined IgM+ and class-switched memory B cells separately. We found that the reduced 
expression of Fc - and complement receptors as well as sIg observed in SLE affected both 
IgM+ and switched memory B cells.  
In humans, B lymphocytes expressing cell surface IgM and CD27 comprise a 
significant proportion of the B-cell population in the peripheral circulation (136). These cells 
have been termed IgM memory B cells because, like conventional class-switched memory 
cells, they possess somatically hypermutated variable region genes and express CD27 
(137;138). Despite the prevalence of IgM-expressing over "classical" class-switched memory 
B cells, the role of IgM- expressing memory cells in T cell-dependent immune responses 
remains elusive. It has been documented recently that in healthy individuals the IgM+ memory 
B cell compartment is depleted of self-reactive and polyreactive antibodies relative to the 
naive B cell pool (139). Thus, transition from naïve B cells into circulating IgM+ memory B 
cells is accompanied by efficient counter-selection against self-reactive naïve B cells before 
the onset of somatic hypermutation. Based on this finding and along with the fact that IgM 
pathogenic autoantibodies are less characteristic for SLE, we suppose that reduced levels of 
IC-binding receptors on IgM+ memory cells may contribute to autoimmunity in a way that is 
different from switched memory cells. Although little is known about the role of IgM+/CD27+ 
B cells in autoimmunity, disturbances in the memory cell compartment may result not only in 
higher susceptibility to infection by encapsulated bacteria, but may also have other 
consequences.  
It has been shown, however, that self-reactive antibodies including antinuclear and 
polyreactive immunglobulins were frequently expressed by IgG+ memory B cells in healthy 
donors.  
Memory B cells can be induced in vitro to differentiate into Ig-secreting plasmablast 
upon stimulation (140-142). The checkpoints controlling the differentiation of self-reactive 
memory B cells into antibody secreting plasma cells has yet to be determined, but it is feasible 
to suppose that abnormal expression of IC-binding receptors on anergic memory B cells may 
provide a signal sufficient to reactivate them. Under normal conditions these cells remain in 
anergic state, but in situations where IC concentrations reach pathological levels, failed up-
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regulation of the inhibitory Fc RII and CR1 on isotype-switched memory B cells may lead to 
activation and autoantibody production. Thus the inhibitory receptors Fc RII and CR1 might 
serve as a final barrier to prevent these B cells from maturing into plasma cells, a function 
lacking in SLE patient.  
In mice, there is accumulating evidence that the inhibitory Fc RII mediates its 
function during late stages of B cell maturation(143). Absence of this receptor resulted in the 
expansion of IgG+ plasma cells secreting autoreactive antibodies, but did not affect early 
events in the bone marrow such as receptor editing, nor did it prevent the development of 
IgM+ autoreactive B cells. In humans, however, there is no documented evidence about the 
role of Fc RII and CR1 in the process of plasmacell differentiation from memory B cells. 
Taken together, we can say that although both IgM+ and switched memory B cells from SLE 
patients expressed lower levels of Fc RII and CR1 on their surface, the functional 
consequences of this reduction may be different in the two memory populations. 
Possible mechanisms responsible for the loss of up-regulation of IC-bindig receptor 
expression on memory B cells in SLE 
Mechanisms, which are responsible for the reduced expression of IC-binding receptors 
in SLE may be due to both inherited and acquired elements. Whether the complement 
containing immune complexes acting as ligands, or antibodies directed against these receptors 
are responsible for the reduction, is unclear (144). We examined the ligand-induced 
modulation of CR1 expression after overnight exposure to immobilized C3b in different B 
cell subpopulations. The natural ligand of CR1 had no effect on CR1 expression in the naïve 
population, but induced the loss of up-regulation of this receptor on memory B cells. This 
effect is not associated with a general down-modulation of membrane antigens, and is 
selectively induced by immobilized C3b which clusters cell surface CR1. The fact that CR1 
aggregation is able to induce receptor down-modulation in a similar manner we observed in 
SLE patients, suggest the ligand-induced regulation of this complement receptor. We found 
that CR1 down-regulation was not readily reversible, since its appearance could not be 
observed after an additional 48 h incubation in the absence of C3b. Since immune complex 
overload is a universal phenomenon in SLE, high levels of complement containing complexes 
may cause reduction in receptor density. Although we found significantly higher levels of 
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CIC in the SLE patients, we could not detect any correlation between CIC levels and receptor 
expression.  
We propose that the observed receptor up-regulation on memory B cells disappears 
once a critical concentration of CIC is exceeded, and further increase in CIC levels does not 
affect receptor levels.  
An alternative way leading to reduced receptor density could be the proteolytic 
cleavage of extracellular domains of membrane proteins (ectodomain shedding). Several 
reports have proved that complement receptors CR1, CR2 as well as the inhibitory Fc RIIb 
from B cells can be released upon activation and might be involved in regulatory processes 
(145;146). Extracellular proteolysis of receptors irreversibly inactivates receptor-mediated 
signalling. In the same time soluble fragments are released into the plasma where they act as 
potential modulators by interacting with their ligands. This provides additional levels of 
regulation (proteinase and receptor), and a higher order of control of cellular function. 
As we could only detect a partial loss of IC-binding receptors from the cell surface, we 
assume that both Fc RII and CR1 segregate into two types of membrane domains, one that is 
susceptible to receptor loss and another that is resistant to this event. Thus, their localization 
determines their accessibility for serine proteases resulting in the shedding of these receptors. 
Terminal differentiation toward plasma cells may also account for the reduced receptor 
densities observed on B cells. Similarly to earlier reports (147;148) we also found a 
significantly higher percentage of CD19+/CD27high plasmablast/early plasma cells and a 
disturbed ratio of naïve and memory B cells in SLE patients. These cells are known to 
proliferate intensively and secrete antibody, thereby being good targets for therapeutic 
interventions. Investigating IC-binding receptors on these terminally differentiated CD27high 
plasmablasts we detected minimal levels of Fc RII, CR1 and sIg both in healthy individuals 
and SLE patients. Minimal levels of inhibitory Fc RII and CR1 on CD27high/sIglow 
plasmablasts suggest that these receptors are probably not involved in the regulation of B cells 
at this differentiation stage and have no influence on antibody production. 
CR1 clustering and BCR-mediated B cell proliferation in healthy donors and SLE patients 
 
Our laboratory has previously shown that heat-aggregated C3 has an inhibitory effect 
on BCR induced B cell proliferation. Aggregated C3 behaves like C3b-like C3 in respect to 
its receptor-binding activity. Because aggregation results in the reduced accessibility of the 
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C3d regions of C3 molecules, it primarily binds to human CR1 and mimics multimeric C3b. 
Ag-bound C3d is known to promote B cell activation by lowering the threshold of Ag-specific 
BCR for activation, however, clustering of CR1 by its natural ligand C3b, inhibits the 
proliferation of B cells activated via the BCR. Now we have shown that clustering of CR1 by 
aggregated C3 on the B cell surface inhibits proliferation dose-dependently both in the case of 
naïve and memory cells, in healthy donors. We have found no difference between the IgM 
and IgG memory compartment, however, CR1 ligation exerted a stronger inhibition on the 
proliferation of naïve cells as compared to memory B lymphocytes. Since we measured higher 
expression levels of CR1 on memory B cells, we assume that the up-regulation of this 
receptor may influence the inhibitory capacity of CR1. It is still an open question, what 
molecular mechanisms are responsible for the inhibition casused by CR1 clustering. 
Human CR1 has no activating and/or inhibitory motifs in its cytoplasmic domains. In 
contrast to CR2, which includes potential tyrosine phosphorylation sites in its cytoplasmic 
tail, the short intracytoplasmic domain of human CR1 does not seem to have the ability of 
transducing signals. The intracellular part of CR1 contains only one potential threonine 
phosphorylation site and two PDZ-motifs (149). A general function of the PDZ domain seems 
to be directing cellular proteins to multiprotein complexes allowing CR1 to associate with 
other membrane proteins or actin cytoskeleton. Actin cytoskeleton is known as a regulator of 
the distribution of membrane regions and proteins upon receptor ligation in lymphocytes 
(150). CR1 molecules in the cell membrane of human B cells appear not only in free form, but 
also in association with CR2, but not within the trimolecular complex of CR2/CD19/CD81 
(151). The role of this CR1/CR2 complex however is yet not clear, but a recent report 
described a co-operation between the two receptors in the internalisation of ligands (152). So 
far no other receptors have been described, which could be associated with CR1 in the cell 
membrane.  
Recent evidence indicates that following antigen binding the BCR rapidly translocates 
into cholesterol- and sphingolipid-rich membrane microdomains termed lipid rafts (153). 
Lipid rafts appear to function as platforms for the induction and regulation of the BCR 
signaling cascades. It has been reported that BCR co-ligated with the CD19/CD21 complex is 
retained within the lipid rafts for considerably longer time than the BCR that is simply cross-
linked to itself (154). Prolonged retention of the BCR in rafts resulted in sustained tyrosine 
phosphorylation of proteins within the lipid microdomains indicating the formation of a long-
lived signaling complex. Independent cross-linking of the BCR and the CD19/CD21 complex 
resulted also in increased residency and signalling, but the duration of the effect was not as 
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prolonged as with co-ligation (154). There is no evidence regarding the membrane 
localization of human CR1. Its strong immunomodulatory potential on BCR-mediated 
proliferation may be explained by its capacity to induce sequestering the BCR receptor from 
other important signalling molecules present in the lipid rafts, thereby destabilize the BCR 
signalling complex. On the other hand CR1 clustering may cause down-regulation of 
signalling by enhancing BCR internalization. 
Investigating the inhibitory effect of CR1 clustering on the BCR-induced proliferation 
of naïve and memory B cells from healthy individuals we could observe stronger inhibition in 
the naïve population. One possible explanation for this observation may be that during 
culturing ligand-induced down-regulation of CR1 happens on memory B cells by shedding 
large amounts of receptors. Soluble CR1 may then cover C3b epitopes in aggregated C3, 
thereby resulting in partial blocking of its inhibitory capacity. One may speculate that under 
physiological conditions the ligand–induced receptor shedding may have similar regulatory 
functions. Our finding that no change could be observed in the inhibitory capacity of CR1 in 
SLE patients, where up-regulation of CR1 on memory B cells is lost, supports this suggestion 
as well.  
 
CR1 ligation does not block the BCR-induced plasmablast formation of memory B cells in 
healthy individuals 
 
Little is known about the formation and maturation of plasmacells (PC) in humans. 
Following immunization, specific Ab-forming cells (AFC) are generated and can be 
transiently detected in the circulation. The nature of these circulating AFC has not been fully 
clarified, and it is possible that they are the main precursors of terminally differentiated PC in 
the bone marrow. Experimental data accumulated in recent years which demonstrate that PC 
are a diverse cell compartment comprising cell subsets differing in several significant respects 
(155). As illustrated in Figure 18, human PC differentiation requires transitions through 
successive maturational steps under the control of several factors (155;156). Memory B cells 
are shown to differentiate into Ig secreting plasmablasts in the presence of antigen and the T 
cell–derived cytokines IL-2 and IL-10, in vitro. Molecules that regulate and modulate this 
transition positively or negatively are under investigation. Since several rounds of divisions 
are necessary to the differentiation, CR1 is a potential receptor that may be able to inhibit the 
BCR-induced plasmablast formation. We determined the relative rates of BCR-mediated 
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differentiation of distinct subsets of human B cells into antibody producing cells in the 
presence of IL-2 and IL-10. Naive B cells yielded <1% of CD27high/sIglow plasmablasts 
following stimulation. In contrast, under the same conditions the frequency of CD27high/sIglow 
B cells increased up to 15-18% in the memory population. We could not observe any 
plasmablast differentiation in the absence of cytokines, therefore it is likely that co-signals 
from cytokine receptors are necessary to differentiation. Although we found that CR1 ligation 
strongly inhibits the BCR-induced proliferation, it had no effect on plasmablast differentiation 
of memory B cells. It is likely that events mediated by cytokines override the inhibitory 








Figure 23. The model of terminal B cell differentiation 
 
CR1 clustering and CpG-mediated B cell proliferation and differentiation in healthy donors 
and SLE patients 
 
Unmetilated bacterial CpG oligonucleotids are potent activators of human B cells 
(157-159). In contrast to the results of Lanzavecchia's group, who reported that only memory 
but not naive B cells proliferate in response to CpG ODN 2006 (101) we observed a strong 
proliferating capacity in the naïve populations, too. The same group have published that naive 
B cells start to proliferate upon CpG stimulus only if they receive simultaneous antigen-
specific stimulation via the BCR. Here we demonstrate that naive B cells may also be 
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activated by polyclonal stimuli in the absence of cognate interaction, without BCR triggering. 
Bernasconi and colleagues have reported that the density of TLR9, the receptor required for 
recognition of CpG motifs, was low on naive B cells but high on memory B cells (160). 
Moreover TLR9 mRNA was rapidly upregulated in naive B cells upon ligation of the BCR. 
Several reports have described that CpG DNA synergizes with BCR mediated signals and 
amplifies B cell proliferation (160). Moreover CpG and BCR-mediated signals were shown to 
integrate at the level of the MAPK, NF-kB activation pathways (161). In contrast to the BCR-
induced proliferation that was strongly inhibited by aggregated C3, our results clearly show 
that CR1 clustering does not interfere with the signalling pathways activated by CpG. 
Altogether these findings suggest that aggregated C3 interferes with the BCR coupling 
network at an earlier stage, i.e. before it becomes integrated with the CpG-pathway. 
A recent study suggests that CpG DNA potentiates B-cell response by enhancing 
terminal differentiation (162). We found that plasmablast formation could be detected only to 
a little extent in the CD27- naïve B cell population upon CpG stimulus. However, in CD27+ B 
cells, a predominant differentiation into plasma cells occurred. 
The relative frequency of CD27high/sIglow plasmablasts increased up to 30% after CpG 
stimulus. Aggregated C3, applied for CR1 clustering on the cell surface, had no influence on 
the plasmablast differentiation of memory cells, indicating that the inhibitory signals mediated 
by CR1 has an effect only at the early stages of differentiation. 
We used ELISPOT assay to assess the generation rate of antibody secreting cells by 
determining the frequency of cells secreting IgM and IgG under the same culture conditions. 
CpG-mediated plasmablast formation of CD27+ memory B cells was accompanied by an 
increased number of IgM but not IgG secreting cells indicative of plasma-cell formation in the 
IgM memory compartment. The differential response to polyclonal stimuli may reflect distinct 
roles of switched and IgM memor B cell subsets. Thus, although the discriminating sensitivity 
of switched memory B cells to help bystander cells may be instrumental in maintaining 
systemic IgG antibody levels, the capacity of IgM memory B cells to respond to CpG in the 
absence of cytokines could be instrumental in maintaining levels of natural antibodies to 
bacterial antigens.  
After stimulation of memory B cells with CpG oligodinucleotid in the presence of IL-
10 cytokine we found a slight increase in the frequency of plasmablast population compared 
to the culture when we used CpG as the only stimulus. The response of memory B cells was 
not significantly affected by the addition of anti-Ig, indicating that the stimulatory conditions 
provided by polyclonal activators were already optimal. Summing up, these results indicate 
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that,  in the absence of specific antigen, only IgM memory B cells proliferate and differentiate 
into antibody-secreting cells in response to polyclonal stimuli derived from microbes, and this 
process could not be inhibited by CR1 clustering. 
In contrast to memory B cells of healthy individuals, B cells from SLE patients failed 
to form IgM secreting plasmablasts upon stimulation with CpG. The failure of CpG to induce 
proliferation of memory B cells in SLE may be due to the fact that TLR9 is either expressed at 
too low levels or is inefficiently coupled to signal transduction pathways. Regarding TLR-9 
expression in B cells from SLE patients there are inconsistent data in the literature. Verthelyi 
et al. have described that the response of PBMC from SLE patients to CpG ODN is abnormal 
(163).The activation of monocytes and dendritic cells was impared, as shown by their 
decreased cytokine secretion. In contrast, the production of IgM and IL-10 by B cells was 
comparable with that of in samples of healthy controls. These authors have also shown that 
reduction in cellular responsiveness to CpG ODN stimulation was not due to a reduction in 
TLR-9 expression. Nakano et al. have demonstrated that mRNA levels of TLR-9 in B cells 
was up-regulated in SLE patients and B cell activation by CpG resulted in enhanced 
production of anti-dsDNA antibodies and IL-10 (164;165). Our results, however, demonstrate 
a decreased ratio of IgM memory B cell population in SLE patients indicating that the low 
number of these cells may be the cause of the defective response to bacterial stimuli. Our 
finding further supports this assumption, because if BCR ligation was applied parallel to the 
CpG stimulus, which may trigger TLR9–up-regulation in B cells, the responsiveness was also 
abolished. 
In conlusion, the reduction in the expression level of IC-binding receptors on CD19+ B 
cells is not only due to a disturbed memory compartment, but the higher frequency of 
CD19+/CD27high plasmablasts expressing very low levels of these receptors. Our functional 
studies further suggest that under physiological conditions the CR1-mediated inhibition might 
have a role in the antigen-dependent homeostasis of memory B cells, but this does not affect 
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Investigations in autoimmune animal models suggest that alterations in the expression or 
function of IC-binding Fc – and complement receptors may contribute to the initiation and 
maintenance of IC-mediated autoimmune disorders. As B cells have a crucial role in the 
pathological processes by producing autoreactive antibodies, examination of the expression 
and role of these IC-binding receptors in the maintenance of B cell tolerance has elemental 
role. 
We carried out a phenotypic analysis of the expression of IC-binding receptors on B 
cells taken from healthy individuals and SLE patients. In spite of individual variations there 
was a significant decrease in the expression of these receptors on B cells of SLE patients 
compared to the age-matched healthy controls. CR1 expression on B cells from SLE patients 
with active disease (SLEDAI>10) was significantly lower compared to healthy controls or 
patients with inactive SLE. Reduction in Fc RII expression was also more pronounced in 
patients with active SLE compared with age-matched controls or patients with inactive SLE. 
We observed a positive correlation between the expression of Fc RII and CR1, indicating that 
these inhibitory receptors are simultaneously down-modulated. We found that the reduced 
expression of Fc RII and CR1 on B cells from SLE patients was unstable over a two-year 
period. 
Distribution of these receptors on distinct B cell subpopulations in the blood has not 
been documented in detail so far, not even in healthy individuals. We found that the 
expression of the inhibitory receptors Fc RII and CR1 is significantly up-regulated on the 
memory B cells of healthy controls; however their expression is considerably decreased on 
memory B cells of SLE patients, reaching the levels of receptor density found on naive cells. 
Regarding the expression of CR2, the co-receptor for BCR, no difference was found between 
naive and memory cells of healthy individuals – in contrast to Fc RII and CR1. In SLE 
however, a reduced expression of CR2 was characteristic for both the naive and memory B 
cells. We found that the reduced expression of Fc - and complement receptors as well as sIg 
observed in SLE affected both IgM+ and switched memory B cells. 
We have shown that clustering of CR1 by aggregated C3 on the B cell surface inhibits 
proliferation dose-dependently both in the case of naïve and memory cells, in healthy donors. 
We have found no difference between the IgM and IgG memory compartment, however, CR1 
ligation exerted a stronger inhibition on the proliferation of naïve cells as compared to 
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memory B lymphocytes. Although we found that CR1 ligation strongly inhibits the BCR-
induced proliferation, it had no effect on plasmablast differentiation of memory B cells. In 
contrast to the BCR-induced proliferation that was strongly inhibited by aggregated C3, our 
results clearly show that CR1 clustering does not interfere with the signalling pathways 
activated by CpG. In the absence of specific antigen, only IgM memory B cells proliferate and 
differentiate into antibody-secreting cells in response to polyclonal stimuli derived from 
microbes, and this process could not be inhibited by CR1 clustering. 
In conlusion, the reduction in the expression level of IC-binding receptors on CD19+ B 
cells is not only due to a disturbed memory compartment, but the higher frequency of 
CD19+/CD27high plasmablasts expressing very low levels of these receptors. Our functional 
studies further suggest that under physiological conditions the CR1-mediated inhibition might 
have a role in the antigen-dependent homeostasis of memory B cells, but this does not affect 














Állatmodellekkel végzett kísérletek igazolják, hogy az IC-köt  Fc - és CR1/CR2 
receptorok expressziójában és funkciójában bekövetkez  zavarok hajlamosító tényez k 
autoimmun betegségek kialakulásában, fenntartásában. Mivel autoreaktív ellenanyagok 
termelése révén a B-sejteknek kitüntetett szerepük van a patológiás folyamatok létrejöttében, 
az IC-köt  receptorok megjelenésének, szerepének vizsgálata a B-sejt tolerancia 
fenntartásában alapvet  fontosságú.  
Munkánk során egészséges donorokból és SLE-ben szenved  betegekb l származó B-
sejteken vizsgáltuk az IC-köt  receptorok sejtfelszíni megjelenését. Szignifikáns csökkenést 
találtunk a betegek B-sejtjein mind az Fc RII mind a komplementreceptorok expresszióját 
tekintve. A CR1 és az Fc RII receptorok esetében a betegség aktivitása nagymértékben 
befolyásolta a sejtfelszíni megjelenést, a CR2 receptor esetében azonban nem volt 
szignifikáns eltérés az aktív és az inaktív csoport között. Kimutattuk, hogy a CR2 esetében a 
betegség aktivitásától függetlenül elkülöníthet  egy a receptort kisebb mértékben kifejez  
csoport. A továbbiakban megvizsgáltuk, hogy az aktív SLE-s csoportban található 
receptorcsökkenés mely B-sejt alpopulációkat érinti. Ezen receptorok expressziós 
mintázatának eltéréseit különböz  B-sejt alpopulációkon eddig egészséges donorokban sem 
vizsgálták. Eredményeink azt mutatják, hogy a gátló CR1 és az Fc RII megjelenése fokozott 
az IgM+ és az izotípusváltáson átesett IgM- memória B-sejteken, szemben a naív B-sejtekkel. 
Míg a CR1 esetébe nem találtunk különbséget a két memóriasejt populáció között, addig az 
Fc RII megjelenése nagyobb mérték  volt az IgM+ memória sejteken. A CR2 esetében nem 
találtunk fokozott expressziót a memória-populáción. A CR1 és a CR2 eltér  megjelenése 
különböz  fiziológiás szerepükre is utal, szemben az egérben kifejez d  CR1/CR2-vel. 
 Aktív SLE-ben szenved k B-sejtjeit vizsgálva nem találtuk az CR1 és az Fc RII 
receptorok memória sejtekre jellemz  fokozott megjelenését. A CR2 csökkenés azonban a 
naív és a memória populációt egyaránt érintette. Az irodalommal megegyez en a 
CD27high/sIglow plazmablaszt populáció nagymérték  növekedését tapasztaltuk SLE-ben. Ezen 
sejteken az IC-köt  receptorok expressziója a kontroll csoportban tapasztaltakhoz hasonlóan 
csekély volt. Longitudinális vizsgálataink arra utalnak, hogy a betegekben található 
receptorcsökkenés a CR1 és az Fc RII esetében átmeneti jelleg . 
  Funkcionális vizsgálatainkban megállapítottuk, hogy egészséges donorokból izolált 
memória B-sejtek BCR által kiváltott proliferációja a naív sejtekhez képest kevésbé gátolható 
a CR1 receptor keresztkötése által. SLE-s betegekb l izolált csökkent CR1 expressziót mutató 
 87
B-sejteket vizsgálva a kontrollhoz képest nem találtunk különbséget a CR1 által kiváltott 
gátlás mértékében. Metilálatlan CpG motívumokat tartalmazó oligonukleotidok által indukált 
B-sejt proliferációt a CR1 receptor aggregációja nem befolyásolta. 
Megállapítottuk, hogy míg a naív és a memória B-sejtek BCR-indukált proliferációját 
a CR1 receptor keresztkötés gátolja, addig a receptor aggregációja nem befolyásolja a 
memória sejtek BCR ill. CpG által indukált plazmablaszt differenciációját. 
Összességében elmondhatjuk, hogy aktív SLE-ben a gátló CR1 és Fc RII receptorok 
csökkenése egyrészt a memória populáció sejtjein az up-reguláció hiányából, másrészt az IC-
köt  receptorokat minimálisan kifejez  plazmablaszt populáció felszaporodásából adódik. 
Funkcionális vizsgálataink arra utalnak, hogy fiziológiás körülmények között a CR1 által 
közvetített gátlásnak a memória B sejtek antigén függ  homeosztázisában lehet szerepe, a 
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